3apos is used; method for sequencing allyl-terminated nucleotides
The use of a palladium catalyst and tris(hydroxyalkyl)phosphine to remove 3'allyl blocking groups during sequencing by synthesis addresses the efficiency and signal loss issues, allowing for extended and reliable DNA sequencing.
Patent Information
- Application Number
- CN202380031861.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-27
- Filing Date
- 2023-12-21
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing sequencing by synthesis (SBS) methods using 3'allyl-terminated nucleotides suffer from low efficiency and rapid loss of signal intensity, limiting their application in commercial DNA sequencing beyond a few cycles.
A method involving a palladium catalyst and tris(hydroxyalkyl)phosphine is used to chemically remove the 3'allyl blocking group during each sequencing cycle, enabling prolonged and efficient DNA sequencing by synthesis, with optional use of labeled or unlabeled nucleotides and altered archaeal DNA polymerase.
The method achieves extended sequencing cycles, improving the reliability and efficiency of SBS by maintaining signal intensity and enabling accurate nucleotide incorporation.
Smart Images

Figure CN119095984A_ABST
Abstract
Description
Background of the Invention Technical Field
[0001] The present disclosure generally relates to polynucleotide sequencing methods, compositions, and kits for sequencing. The present disclosure also relates to methods for removing 3' blocking groups. Background Art
[0002] Progress in molecular research has always been driven, in part, by improvements in techniques used to characterize molecules or their biological reactions. In particular, research on nucleic acids, DNA and RNA, has benefited from the development of techniques for sequence analysis and the study of hybridization events.
[0003] An example of the technology of improved nucleic acid research is to develop an assembly array of immobilized nucleic acids. These arrays are usually composed of a high-density matrix of polynucleotides fixed to a solid support material. See, for example, Fodor et al., Trends Biotech. 12: 19-26, 1994, which describes a method for assembling nucleic acids using a chemically sensitized glass surface, which is protected by a mask but exposed in a limited area to allow attachment of appropriately modified nucleotide phosphoramidites. Assembly arrays can also be manufactured by "spotting" known polynucleotides to predetermined positions on a solid support (e.g., Stimpson et al., Proc. Natl. Acad. Sci. 92: 6379-6383, 1995).
[0004] One method of determining the nucleotide sequence of nucleic acids bound to an array is called "sequencing by synthesis" or "SBS". Ideally, this technique for determining the nucleotide sequence of DNA requires the controlled incorporation (i.e., one at a time) of the correct complementary nucleotide opposite to the nucleic acid being sequenced. This enables accurate sequencing by adding nucleotides in multiple cycles, since only one nucleotide residue is sequenced at a time, thereby preventing uncontrolled incorporation of nucleotide sequences. The incorporated nucleotides are read using an appropriate label attached to the incorporated nucleotides, after which the label portion is removed and the next round of sequencing is performed.
[0005] To ensure that only a single nucleotide is incorporated, a structural modification ("protecting group" or "capping group") is included in each labeled nucleotide, which is added to the growing chain to ensure that only one nucleotide is incorporated. After the nucleotide with the protecting group is added, the protecting group is removed under reaction conditions that do not interfere with the integrity of the DNA being sequenced. The sequencing cycle can then continue with the incorporation of the next protected labeled nucleotide. In order to be used for DNA sequencing, nucleotides (usually nucleotide triphosphates) generally require a 3'-hydroxyl capping group to prevent the polymerase used to incorporate it into the polynucleotide chain from continuing to replicate once a base is added to the nucleotide.
[0006] Reversible protecting groups have been described before. For example, Metzker et al. (Nucleic Acids Research, 22 (20): 4259-4267, 1994) disclose the synthesis and use of eight 3'-modified 2-deoxyribonucleoside 5'-triphosphates (3'-modified dNTPs), and test their incorporation activity in two DNA template assays. WO 2002 / 029003 describes a sequencing method that may include using an allyl protecting group in a polymerase reaction to cap the 3'-OH group on the growing DNA chain. In addition, the development of many reversible protecting groups and methods for removing these protecting groups under DNA compatible conditions have been reported previously in International Application Patent Publication Nos. WO 2004 / 018497 and WO 2014 / 139596, each of which is hereby incorporated by reference in its entirety. Although the use of 3'allyl-terminated nucleotides has been reported 20 years ago, due to various factors including the low efficiency of 3' capping group cleavage chemistry and the rapid loss of signal intensity during sequencing, SBS using such nucleotides has never been successfully applied in a commercial environment for long DNA reading. For example, Ju et al. reported four-color DNA sequencing while synthesis using 3'allyl-terminated nucleotides, and reported only 25 cycles of SBS, wherein only after five cycles, the fluorescence intensity was significantly lost. See Ju et al., PNAS, 2006, 103 (52): 19635-19640. Therefore, there is still a need to improve sequencing conditions (e.g., cleavage conditions of 3'allyl-terminated groups) and sequencing indicators of SBS using nucleotides with 3'allyl-terminated groups. Summary of the invention
[0007] One aspect of the present disclosure relates to a method for determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising:
[0008] (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein:
[0009] (i) the solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises multiple copies of the target polynucleotide;
[0010] (ii) the solid support comprises a plurality of different target polynucleotides; and
[0011] (iii) the sequencing primer is complementary to at least a portion of the different target polynucleotide;
[0012] (b) contacting the solid support with an aqueous solution comprising a DNA polymerase and nucleotides A, G, C and T or U, wherein each nucleotide comprises a 3′ allyl capping group attached to a 3′ oxygen atom, under conditions suitable for DNA polymerase-mediated primer extension. The 2′ deoxyribose moiety;
[0013] (c) imaging the solid support to determine the identity of the incorporated nucleotide;
[0014] (d) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for chemically removing the 3'-allyl blocking group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support;
[0015] (e) contacting the solid support with an aqueous washing solution; and
[0016] (f) Repeating steps (b) to (e) to determine the target polynucleotide sequence.
[0017] Another aspect of the present disclosure relates to a method of determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising:
[0018] (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein:
[0019] (i) the solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises multiple copies of the target polynucleotide;
[0020] (ii) the solid support comprises a plurality of different target polynucleotides; and
[0021] (iii) the sequencing primer is complementary to at least a portion of a different target polynucleotide;
[0022] (b) contacting the solid support with an aqueous solution comprising a DNA polymerase and nucleotides A, G, C and T or U under conditions suitable for DNA polymerase-mediated primer extension, wherein:
[0023] (i) each of the at least three types of nucleotides independently comprises a base attached to a detectable label via a cleavable linker, and the cleavable linker comprises a moiety selected from the group consisting of:
[0024] and * indicates the position where this portion is attached to the rest of the nucleotides;
[0025] (ii) each nucleotide comprises a 3′ allyl group attached to the 3′ oxygen atom The 2′ deoxyribose moiety of
[0026] (iii) the DNA polymerase is an altered archaeal DNA polymerase;
[0027] (c) contacting the solid support with a solution comprising one or more free radical scavengers and imaging the solid support to determine the identity of the incorporated nucleotide;
[0028] (d) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for (i) chemically removing the 3'-allyl blocking group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support; and (ii) chemically removing the detectable label attached via the cleavable linker;
[0029] (e) contacting the solid support with an aqueous wash solution comprising a palladium scavenger; and
[0030] (f) Repeating steps (b) to (e) to determine the target polynucleotide sequence.
[0031] Another aspect of the present disclosure relates to a method of determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising:
[0032] (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein:
[0033] (i) the solid support comprises at least 5,000,000 spatially distinguishable sites / cm2, each of which comprises a plurality of copies of a target polynucleotide;
[0034] (ii) the solid support comprises a plurality of different target polynucleotides; and
[0035] (iii) the sequencing primer is complementary to at least a portion of the different target polynucleotide;
[0036] (b) contacting the solid support with an aqueous solution comprising a DNA polymerase and nucleotides A, G, C and T or U under conditions suitable for DNA polymerase-mediated primer extension, wherein:
[0037] (i) at least one of the nucleotides comprises a base attached to a detectable label via a cleavable linker; and
[0038] (ii) the nucleotides each comprise a 3′ allyl capping group having a 3′ allyl group attached to the 3′ oxygen atom The 2′ deoxyribose moiety;
[0039] (c) contacting the solid support with a solution comprising one or more free radical scavengers and imaging the solid support to determine the identity of the incorporated nucleotide;
[0040] (d) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for (i) chemically removing the 3'-allyl group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support; and (ii) chemically removing the detectable label attached via the cleavable linker;
[0041] (e) contacting the solid support with an aqueous washing solution; and
[0042] (f) Repeating steps (b) to (e) to determine the target polynucleotide sequence.
[0043] Another aspect of the present disclosure relates to a method of determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising:
[0044] (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein:
[0045] (i) the solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises multiple copies of the target polynucleotide;
[0046] (ii) the solid support comprises a plurality of different target polynucleotides; and
[0047] (iii) the sequencing primer is complementary to at least a portion of the different target polynucleotide;
[0048] (b) contacting the solid support with an aqueous spike-in mixture comprising a DNA polymerase and one or more of the four types of nucleotides A, G, C and T or U under conditions suitable for DNA polymerase-mediated primer extension, wherein:
[0049] (i) the nucleotides each comprise a 3′ allyl capping group attached to the 3′ oxygen atom
[0050] The 2′ deoxyribose moiety;
[0051] (ii) at least one type of nucleotide is unlabeled; and
[0052] (iii) a first type of unlabeled nucleotide comprising a first functional moiety;
[0053] (c) contacting the extended copy polynucleotide with an aqueous labeling mixture comprising a first labeling reagent, wherein the first labeling reagent comprises one or more first detectable labels and a first binding portion capable of specifically binding to a first functional portion of a first type of unlabeled nucleotide;
[0054] (d) imaging the solid support and performing one or more fluorescence measurements to determine the identity of the incorporated nucleotide;
[0055] (e) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for (i) chemically removing the 3'allyl group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support;
[0056] (f) contacting the solid support with an aqueous washing solution; and
[0057] (g) Repeating steps (b) to (f) to determine the target polynucleotide sequence.
[0058] A further aspect of the present disclosure relates to a sequencing kit, the sequencing kit comprising:
[0059] (a) comprising a DNA polymerase and a doping mixture of nucleotides A, G, C and T or U, wherein:
[0060] (i) The nucleotide comprises a 3′ allyl group attached to the 3′ carbon atom The 2′ deoxyribose moiety of
[0061] (ii) the DNA polymerase is an altered archaeal DNA polymerase;
[0062] (b) an aqueous deblocking solution comprising a palladium catalyst, a tris(hydroxyalkyl)phosphine, and one or more buffer reagents, the aqueous deblocking solution being suitable for (i) chemically removing the 3′-allyl group from the incorporated nucleotide to expose the 3′-OH group for further nucleotide incorporation on the solid support; and (ii) chemically removing a detectable label attached via a cleavable linker; and
[0063] (c) an aqueous wash solution comprising a Pd(II) scavenger;
[0064] The kit is configured to perform at least about 100 cycles of sequencing by synthesis.
[0065] In some embodiments of the methods or kits described herein, the tris(hydroxyalkyl)phosphine comprises or is tris(hydroxypropyl)phosphine (THPP). BRIEF DESCRIPTION OF THE DRAWINGS
[0066] Figure 1 is a line graph of the peak area percentage of nucleosides with 3' allyl end capping groups compared to nucleosides with 3' AOM end capping groups as a function of time in a Pd cleavage solution kinetic assay.
[0067] Figure 2 is a line graph of the percentage of 3'-OH nucleoside monophosphate formed as a function of time in a solution kinetic assay of Pd cleavage of three different 3'-capped nucleoside monophosphates.
[0068] Figure 3A It is in Illumina's iSeq100 TM Line graph of percent error rate for a standard sequencing-by-synthesis run on the instrument using three different fully functionalized T nucleotides (ffT) with either a 3' allyl capping group or a 3' AOM capping group.
[0069] Figure 3B It is in Illumina's iSeq100 TM Line graph of the phasing percentage for a standard sequencing-by-synthesis run performed on the instrument using three different fully functionalized T nucleotides (ffT) with either a 3' allyl capping group or a 3' AOM capping group.
[0070] Figure 4A It is from Illumina Line graph of percent error rate for sequencing-by-synthesis runs performed on-instrument in a post-incorporation labeling workflow using two different fully functionalized T nucleotides (ffT) with either a 3′ allyl capping group or a 3′ AOM capping group.
[0071] Figure 4B It is from Illumina Line graph of the phasing percentage of sequencing by synthesis runs performed on the instrument in a post-incorporation labeling workflow using two different fully functionalized T nucleotides (ffT) with either a 3' allyl capping group or a 3' AOM capping group. DETAILED DESCRIPTION
[0072] Some aspects of the present disclosure relate to methods for nucleic acid sequencing using nucleotides with 3' allyl capping groups. In particular, the sequencing methods described herein relate to the use of a Pd(0) catalyst formed by a Pd(II) complex and a water-soluble tri(hydroxyalkyl)phosphine to cleave the 3' allyl capping group after each cycle of sequencing by synthesis. In some embodiments, the water-soluble phosphine is THPP. The method further relates to the use of a Pd(0) and / or Pd(II) scavenger. In other embodiments, the nucleotides used in the incorporation step of the sequencing method are labeled nucleotides, wherein the detectable label is covalently attached to the nucleobase via a cleavable linker containing an allyl moiety. The 3' allyl capping nucleotides can be used in a standard SBS setting for labeled nucleotides, or in a post-incorporation labeling workflow for unlabeled nucleotides.
[0073] definition
[0074] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The use of the term "comprising" and other forms such as "including" is not restrictive. The use of the term "having" is not restrictive. As used in this specification, whether in a transitional phrase or in the body of the claims, the terms "comprising" and "including" are to be interpreted as having an open-ended meaning. That is, the above terms should be interpreted synonymously with the phrases "at least having" or "at least including". For example, when used in the context of a process, the term "comprising" means that the process includes at least the listed steps, but may also include additional steps. When used in the context of a compound, composition, or device, the term "comprising" means that the compound, composition, or device includes at least the listed features or components, but may also include additional features or components.
[0075] Where a range of values is provided, it is understood that the upper and lower limit of that range and every intervening value between the upper and lower limits is encompassed within the embodiments.
[0076] As used herein, common organic abbreviations are defined as follows:
[0077] ℃ Temperature in degrees Celsius
[0078] dATP deoxyadenosine triphosphate
[0079] dCTP deoxycytidine triphosphate
[0080] dGTP deoxyguanosine triphosphate
[0081] dTTP deoxythymidine triphosphate
[0082] ddNTP dideoxynucleotide triphosphate
[0083] ffN Fully functionalized nucleotides
[0084] ffA Fully functionalized "A" nucleotide
[0085] ffC Fully functionalized "C" nucleotides
[0086] ffT Fully functionalized "T" nucleotides
[0087] ffG Fully functionalized "G" nucleotides
[0088] IMX doping mixture
[0089] Pd Palladium
[0090] RT Room temperature
[0091] SBS Sequencing by Synthesis
[0092] TCEP Tris(2-carboxyethyl)phosphine
[0093] THPP Tri(hydroxypropyl)phosphine
[0094] As used herein, the term "array" refers to a group of different probe molecules connected to one or more substrates so that these different probe molecules can be distinguished from each other according to relative position. The array may include different probe molecules at different addressable positions located on the substrate. Alternatively or additionally, the array may include a separate substrate with different probe molecules, wherein different probe molecules can be identified according to the position of the substrate on the surface to which the substrate is attached or according to the position of the substrate in the liquid. The exemplary array wherein the separate substrate is located on the surface includes but is not limited to those comprising beads in the hole, such as described in U.S. Patent No. 6,355,431B1, US2002 / 0102578 and PCT Publication No. WO 00 / 63437. For example, in U.S. Patent No. 6,524,793, it is described that the exemplary form of beads in the liquid array can be used for example using a microfluidic device, such as a fluorescence activated cell sorter (FACS) is distinguished. Additional examples of arrays that can be used in the present invention include, but are not limited to, U.S. Pat. Nos. 5,429,807; 5,436,327; 5,561,071; 5,583,211; 5,658,734; 5,837,858; 5,874,219; 5,919,523; 6,136,269; 6,287,768; 6,287,776; 6,288,220; 6,297,006; 6,291,193; 6,346,413; 6,416,949; 6,482,591; 6,514,751 and 6,610,482; and WO 93 / 17126; WO 95 / 11995; WO 95 / 35505; EP 742 287; and EP Those described in 799 897.
[0095] As used herein, the term "covalently attached" or "covalently bonded" refers to the formation of a chemical bond characterized by the sharing of electron pairs between atoms. For example, a covalently linked polymer coating refers to a polymer coating that forms a chemical bond with a functionalized surface of a substrate, as opposed to being attached to the surface via other means (e.g., adhesion or electrostatic interactions). It should be understood that a polymer covalently attached to a surface may also be bonded via means other than covalent attachment.
[0096] As used herein, any "R" group refers to a substituent that may be attached to the designated atom. The R group may be substituted or unsubstituted.
[0097] It should be understood that certain group naming conventions may include either a monoradical or a diradical, depending on the context. For example, when a substituent requires two points of attachment to the rest of the molecule, it should be understood that the substituent is a diradical. For example, a substituent identified as an alkyl group requiring two points of attachment includes a diradical, such as -CH2-, -CH2CH2-, -CH2CH(CH3)CH2-, etc. Other group naming conventions clearly indicate that the group is a diradical, such as "alkylene" or "alkenylene".
[0098] As used herein, the term "halogen" or "halo" means any of the radioactive stable atoms of column 7 of the periodic table, for example, fluorine, chlorine, bromine or iodine, with fluorine and chlorine being preferred.
[0099] As used herein, "C" wherein "a" and "b" are integers a To C b ”, “C a -C b ” or “C a-b" refers to the number of carbon atoms in an alkyl, alkenyl, or alkynyl group, or the number of ring atoms in a cycloalkyl or aryl group. That is, the rings of alkyl, alkenyl, alkynyl, cycloalkyl, and aryl groups can contain from "a" to "b" (inclusive) carbon atoms. For example, a "C1 to C4 alkyl" group refers to all alkyl groups having from 1 to 4 carbons, i.e., CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2 CH2-, CH3CH2CH(CH3)- and (CH3)3C-; C3 to C4 cycloalkyl groups refer to all cycloalkyl groups having 3 to 4 carbon atoms, i.e., cyclopropyl and cyclobutyl. Similarly, a "4 to 6 membered heterocyclyl" group refers to all heterocyclyl groups having 4 to 6 total ring atoms, such as azetidine, oxetane, oxazoline, pyrrolidine, piperidine, piperazine, morpholine, etc. If there is no alkyl, alkenyl, alkynyl, cycloalkyl or aryl group, the alkyl group may be used. If "a" and "b" are specified, the broadest range described in these definitions will be assumed. As used herein, the term "C1-C6" includes C1, C2, C3, C4, C5, and C6, as well as ranges defined by either of these two numbers. For example, C1-C6 alkyl includes C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl, C2-C6 alkyl, C1-C3 alkyl, etc. Similarly, C2-C6 alkenyl includes C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl, and C6 alkenyl. C3-C8 cycloalkyl groups include hydrocarbon rings containing 3, 4, 5, 6, 7 and 8 carbon atoms or ranges defined by any two numbers, such as C3-C7 cycloalkyl groups or C5-C6 cycloalkyl groups.
[0100] As used herein, "alkyl" refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., does not contain double bonds and triple bonds). An alkyl group may have 1 to 20 carbon atoms (whenever it appears in this article, a numerical range such as "1 to 20" refers to each integer in the given range; for example, "1 to 20 carbon atoms" means that the alkyl group may be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, but this definition also covers the term "alkyl" in which no numerical range is specified). An alkyl group may also be a medium-sized alkyl group having 1 to 9 carbon atoms. An alkyl group may also be a low-sized alkyl group having 1 to 6 carbon atoms. An alkyl group may be designated as "C 1- C4 alkyl" or similar designations. By way of example only, "C 1-"C6 alkyl" means that there are one to six carbon atoms in the alkyl chain, that is, the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. Typical alkyl groups include, but are by no means limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.
[0101] As used herein, "alkoxy" refers to a radical of the formula --OR (wherein R is an alkyl radical as defined above), such as "C 1- "C9 alkoxy" includes, but is not limited to, methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy and tert-butoxy, etc.
[0102] As used herein, "alkenyl" refers to a straight or branched hydrocarbon chain containing one or more double bonds. An alkenyl group can have from 2 to 20 carbon atoms, but this definition also encompasses the term "alkenyl" where no numerical range is specified. An alkenyl group can also be a medium-sized alkenyl group having from 2 to 9 carbon atoms. An alkenyl group can also be a low-sized alkenyl group having from 2 to 6 carbon atoms. An alkenyl group can be designated as "C 2- C6 alkenyl" or similar designations. By way of example only, "C 2- "C6 alkenyl" means that there are two to six carbon atoms in the alkenyl chain, that is, the alkenyl chain is selected from the group consisting of ethenyl, propen-1-yl, propen-2-yl, propen-3-yl, buten-1-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-1-yl, 2-methyl-propen-1-yl, 1-ethyl-ethen-1-yl, 2-methyl-propen-3-yl, buta-1,3-dienyl, buta-1,2-dienyl and buta-1,2-dien-4-yl. Typical alkenyl groups include, but are by no means limited to, ethenyl, propenyl, butenyl, pentenyl and hexenyl, etc.
[0103] The term "aromatic" refers to a ring or ring system having a conjugated π electron system, and includes both carbocyclic aromatic groups (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine). The term includes monocyclic groups or fused-ring polycyclic (i.e., rings that share adjacent pairs of atoms) groups, provided that the entire ring system is aromatic.
[0104] As used herein, "aryl" refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent carbon atoms) that contains only carbon in the ring backbone. When aryl is a ring system, each ring in the ring system is aromatic. Aryl groups can have 6 to 18 carbon atoms, but this definition also covers the term "aryl" that appears without a specified numerical range. In some embodiments, aryl groups have 6 to 10 carbon atoms. Aryl groups can be designated as "C6-C 10 Aryl", "C6 or C 10Examples of aryl groups include, but are not limited to, phenyl, naphthyl, azulenyl, and anthracenyl.
[0105] "Aralkyl" or "arylalkyl" is an aryl group attached as a substituent through an alkylene group, such as "C 7-14 "Aralkyl" and the like, including but not limited to benzyl, 2-phenylethyl, 3-phenylpropyl and naphthylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., C 1- C6 alkylene group).
[0106] As used herein, "aryloxy" refers to RO-, where R is aryl as defined above, such as but not limited to phenyl.
[0107] As used herein, "heteroaryl" refers to an aromatic ring or ring system (i.e., two or more condensed rings sharing two adjacent atoms) containing one or more heteroatoms (i.e., elements other than carbon, including but not limited to nitrogen, oxygen and sulfur) in the ring skeleton. When heteroaryl is a ring system, each ring in the ring system is aromatic. The heteroaryl group can have 5 to 18 ring members (i.e., the number of atoms (including carbon atoms and heteroatoms) constituting the ring skeleton), but the present definition also encompasses the term "heteroaryl" in which no numerical range is specified. In some embodiments, the heteroaryl group has 5 to 10 ring members or 5 to 7 ring members. The heteroaryl group can be named "5 to 7 yuan heteroaryl", "5 to 10 yuan heteroaryl" or similar names. Examples of heteroaryl rings include, but are not limited to, furanyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothiophenyl.
[0108] "Heteroaralkyl" or "heteroarylalkyl" is a heteroaryl group attached as a substituent via an alkylene group. Examples include, but are not limited to, 2-thienylmethyl, 3-thienylmethyl, furanylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., C 1- C6 alkylene group).
[0109] As used herein, "carbocyclyl" means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system skeleton. When the carbocyclyl is a ring system, two or more rings can be joined together in a fused, bridged or spiro manner. The carbocyclyl can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. Therefore, carbocyclyl includes cycloalkyl, cycloalkenyl and cycloalkynyl. The carbocyclyl group can have 3 to 20 carbon atoms, but this definition also covers the term "carbocyclyl" in which no numerical range is specified. The carbocyclyl group can also be a medium-sized carbocyclyl with 3 to 10 carbon atoms. The carbocyclyl group can also be a carbocyclyl with 3 to 6 carbon atoms. The carbocyclyl group can be named "C 3- C6 carbocyclyl" or similar designations. Examples of carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicyclo[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.
[0110] As used herein, "cycloalkyl" means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0111] As used herein, "heterocyclyl" refers to a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. The heterocyclyl group can be joined together in a fused, bridged or spiro manner. The heterocyclyl group can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. The heteroatom can be present in a non-aromatic ring or an aromatic ring in the ring system. The heterocyclyl group can have 3 to 20 ring members (i.e., the number of atoms (including carbon atoms and heteroatoms) constituting the ring backbone), but this definition also covers the term "heterocyclyl" in which no numerical range is specified. The heterocyclyl group can also be a medium-sized heterocyclyl group with 3 to 10 ring members. The heterocyclyl group can also be a heterocyclyl group with 3 to 6 ring members. The heterocyclyl group can be named "3 to 6-membered heterocyclyl" or similar names. In preferred six-membered monocyclic heterocyclyls, the heteroatoms are selected from one to a maximum of three from O, N or S, and in preferred five-membered monocyclic heterocyclyls, the heteroatoms are selected from one or two heteroatoms selected from O, N or S. Examples of heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidinedionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxinyl, 1,4-dioxinyl, 1,4-dioxinyl, 1,3-oxathianyl, 1,4-oxathianyl, 1,4-oxathianyl, 2 H-1,2-oxazinyl, trioxanyl, hexahydro-1,3,5-triazinyl, 1,3-dioxolyl, 1,3-dioxolanyl, 1,3-dithienyl, 1,3-dithianyl, isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinone, thiazolinyl, thiazolidinyl, 1,3-oxathiolanyl, indolinyl, isoindolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydrothiopyranyl, tetrahydro-1,4-thiazinyl, thiomorpholinyl, dihydrobenzofuranyl, benzimidazolidinyl and tetrahydroquinoline.
[0112] As used herein, "(aryl)alkyl" refers to an aryl group as defined above attached as a substituent via an alkylene group as described above. The alkylene and aryl groups of the aralkyl group may be substituted or unsubstituted. Examples include, but are not limited to, benzyl, 2-phenylalkyl, 3-phenylalkyl, and naphthylalkyl. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.
[0113] As used herein, "(heteroaryl)alkyl" refers to a heteroaryl group as defined above attached as a substituent via an alkylene group as defined above. The alkylene and heteroaryl groups of the heteroaralkyl group may be substituted or unsubstituted. Examples include, but are not limited to, 2-thienylalkyl, 3-thienylalkyl, furanylalkyl, thienylalkyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl, and their benzo-fused analogs. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.
[0114] As used herein, "(heterocyclyl)alkyl" refers to a heterocycle or heterocyclyl group as defined above connected as a substituent via an alkylene group as defined above. The alkylene group and heterocyclyl group of the (heterocyclyl)alkyl can be substituted or unsubstituted. Examples include, but are not limited to, (tetrahydro-2H-pyran-4-yl)methyl, (piperidin-4-yl)ethyl, (piperidin-4-yl)propyl, (tetrahydro-2H-thiopyran-4-yl)methyl and (1,3-thiazin-4-yl)methyl. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5 or 6 methylene units.
[0115] As used herein, "(carbocyclyl)alkyl" refers to a carbocyclyl group (as defined herein) attached as a substituent via an alkylene group. Examples include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, and cyclohexylpropyl. In some embodiments, the alkylene group is an unsubstituted straight chain containing 1, 2, 3, 4, 5, or 6 methylene units.
[0116] As used herein, "alkoxyalkyl" or "(alkoxy)alkyl" refers to an alkoxy group attached via an alkylene group, such as C2-C8alkoxyalkyl or (C1-C6alkoxy)C1-C6alkyl, for example -(CH2) 1-3 -OCH3.
[0117] As used herein, "-O-alkoxyalkyl" or "-O-(alkoxy)alkyl" refers to an alkoxy group attached via an -O-(alkylene) group, such as -O-(C1-C6alkoxy)C1-C6alkyl, e.g. -O-(CH2) 1-3 -OCH3.
[0118] As used herein, "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen (e.g., monohaloalkyl, dihaloalkyl, and trihaloalkyl). Such groups include, but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1-chloro-2-fluoromethyl, 2-fluoroisobutyl. The haloalkyl group may be substituted or unsubstituted.
[0119] As used herein, "haloalkoxy" refers to an alkoxy group in which one or more hydrogen atoms are replaced by a halogen (e.g., monohaloalkoxy, dihaloalkoxy, and trihaloalkoxy). Such groups include, but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 1-chloro-2-fluoromethoxy, 2-fluoroisobutoxy. The haloalkoxy group may be substituted or unsubstituted.
[0120] An "amino" group refers to a -NH2 group. As used herein, the term "monosubstituted amino group" refers to an amino (-NH2) group in which one hydrogen atom is replaced by a substituent. As used herein, the term "disubstituted amino group" refers to an amino (-NH2) group in which each of the two hydrogen atoms is replaced by a substituent. As used herein, the term "optionally substituted amino" refers to a -NR A R B Group, where R A and R B and R is independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl or heterocyclyl(alkyl), as defined herein.
[0121] An "O-carboxyl" group is one in which R is selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 Aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl "-OC(=O)R" groups are as defined herein.
[0122] A "C-carboxyl" group is one in which R is selected from the group consisting of hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 The "-C(=O)OR" group of the group consisting of aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl, as defined herein. Non-limiting examples include carboxyl (ie, -C(=O)OH).
[0123] A "sulfonyl" group is a group in which R is selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 The "-SO2R" group of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclyl are as defined herein.
[0124] A "sulfinyl" group refers to a "-S(=O)OH" group.
[0125] A "sulfo" group refers to a "-S(=O)2OH" or a "-SO3H" group.
[0126] A "sulfonate" group refers to a "-SO3" group.
[0127] A "sulfate" group refers to a "-SO4ˉ" group.
[0128] An "S-sulfonamido" group refers to a group in which R A and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-SO2NR" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A R B " group, as defined herein.
[0129] An "N-sulfonamido" group is one in which R A and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-N(R)" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A )SO2R B " group, as defined herein.
[0130] A "C-amido" group is one in which R A and R B are each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-C(=O)NR" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A R B " group, as defined herein.
[0131] An "N-amido" group is one in which R A and R Bare each independently selected from hydrogen, C 1- C6 alkyl, C 2- C6 alkenyl, C 2- C6 alkynyl, C 3- C7 carbocyclic group, C 6- C 10 "-N(R)" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A )C(=O)R B " group, as defined herein.
[0132] An "O-carbamyl" group refers to a "-OC(=O)N(R A R B )" group, wherein R A and R B The O-carbamyl group may be substituted or unsubstituted.
[0133] An "N-carbamyl" group refers to an "ROC(=O)N(R A ) - " group, where R and R A The same definition as for N-sulfonylamino may be used. The N-carbamoyl group may be substituted or unsubstituted.
[0134] An "O-thiocarbamyl" group refers to an "-OC(=S)-N(R A R B )" group, wherein R A and R B The O-thiocarbamoyl group may be substituted or unsubstituted.
[0135] An "N-thiocarbamyl" group refers to an "ROC(=S)N(R A )-" group, where R and R A The same definition as for N-sulfonylamino group may be used. The N-thiocarbamoyl group may be substituted or unsubstituted.
[0136] The term "alkylamino" or "(alkyl)amino" refers to an amino group in which one or both hydrogen atoms are replaced by an alkyl group.
[0137] An "(alkoxy)alkyl" group refers to an alkoxy group attached through an alkylene group, such as "(C 1- C6 alkoxy)C 1- C6 alkyl" etc.
[0138] The term "hydroxyl" as used herein refers to an -OH group.
[0139] The term "cyano" as used herein refers to a "-CN" group.
[0140] The term "azido" as used herein refers to a -N3 group.
[0141] When a group is described as "optionally substituted," it may be unsubstituted or substituted. Likewise, when a group is described as "substituted," the substituents may be selected from one or more of the indicated substituents. As used herein, a substituted group is derived from an unsubstituted parent group in which there has been an exchange of one or more hydrogen atoms with another atom or group.Unless otherwise specified, when a group is considered to be "substituted", it means that the group is substituted by one or more substituents independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C3-C7 carbocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 3-10 membered heterocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 3-10 membered heterocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), (aryl)C1-C6 alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), (5-10 membered heteroaryl)C1-C6 alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), halo, -CN, hydroxy, C1-C6 alkoxy, (C1-C6 alkoxy)C1-C6 alkyl, -O(C1-C6 alkoxy)C1-C6 alkyl; (C1-C6 haloalkoxy)C1-C6 alkyl; -O(C1-C6 haloalkoxy) C1-C6 alkyl; aryloxy, thiol (sulfhydryl), halo(C1-C6)alkyl (e.g., –CF3), halo(C1-C6)alkoxy (e.g., –OCF3), C1-C6 alkylthio, arylthio, amino, amino(C1-C6)alkyl, nitro, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-acylamino, N-acylamino, S-sulfonylamino, N-sulfonylamino, C-carboxyl, O-carboxyl, acyl, cyanate, isocyanate, thiocyanate, isothiocyanate, sulfinyl, sulfonyl, -SO3H, sulfonate, sulfate, sulfinyl, -OSO2C. 1-4 Alkyl, monophosphate, diphosphate, triphosphate and oxo (=0). Wherever a group is described as "optionally substituted", the group may be substituted with the above substituents.
[0142] As will be appreciated by those of ordinary skill in the art, the compounds described herein may exist in an ionized form, for example, -CO2 ˉ 、-SO3 ˉ or –O-SO3 ˉ If the compound contains a positively or negatively charged substituent group, e.g., -SO3 ˉ , it may also contain negatively or positively charged counterions so that the compound is neutral as a whole. In other aspects, the compound may exist in the form of a salt, wherein the counterion is provided by a conjugate acid or base.
[0143] As used herein, "nucleotides" include nitrogenous heterocyclic bases, sugars, and one or more phosphate groups. They are monomeric units of nucleic acid sequences. In RNA, the sugar is ribose, and in DNA it is deoxyribose, i.e., a sugar lacking the hydroxyl groups present in ribose. The nitrogenous heterocyclic bases may be purine or pyrimidine bases. Purine bases include adenine (A) and guanine (G) and their modified derivatives or analogs, such as 7-deazaadenine or 7-deazaguanine. Pyrimidine bases include cytosine (C), thymine (T) and uracil (U) and their modified derivatives or analogs. The C-1 atom of deoxyribose is bonded to the N-1 of pyrimidine or the N-9 of purine.
[0144] As used herein, "nucleoside" is structurally similar to a nucleotide, but lacks a phosphate moiety. An example of a nucleoside analog is a nucleoside analog in which a label is attached to a base and no phosphate group is attached to a sugar molecule. The term "nucleoside" is used herein in the conventional sense as understood by those skilled in the art. Examples include, but are not limited to, ribonucleosides comprising a ribose moiety and deoxyribonucleosides comprising a deoxyribose moiety. A modified pentose moiety is a pentose moiety in which an oxygen atom has been replaced by a carbon and / or a carbon has been replaced by a sulfur or oxygen atom. A "nucleoside" is a monomer that may have a substituted base and / or sugar moiety. In addition, nucleosides may be incorporated into larger DNA and / or RNA polymers and oligomers.
[0145] The term "purine base" is used herein with the common meaning understood by those skilled in the art, and includes its tautomers. Similarly, the term "pyrimidine base" is used herein with the common meaning understood by those skilled in the art, and includes its tautomers. The non-limiting list of optionally substituted purine bases includes purine, adenine, guanine, deazapurine, 7-deazaadenine, 7-deazaguanine, hypoxanthine, xanthine, alloxanthine, 7-alkylguanine (e.g., 7-methylguanine), theobromine, caffeine, uric acid, and isoguanine. The example of pyrimidine bases includes, but is not limited to, cytosine, thymine, uracil, 5,6-dihydrouracil, and 5-alkylcytosine (e.g., 5-methylcytosine).
[0146] As used herein, when an oligonucleotide or polynucleotide is described as "comprising" or "incorporating" a nucleoside or nucleotide as described herein, this means that the nucleoside or nucleotide as described herein forms a covalent bond with the oligonucleotide or polynucleotide. Similarly, when a nucleoside or nucleotide is described as a part of an oligonucleotide or polynucleotide, such as "incorporated into" an oligonucleotide or polynucleotide, this means that the nucleoside or nucleotide as described herein forms a covalent bond with the oligonucleotide or polynucleotide. In some such embodiments, a covalent bond is formed between the 5' phosphate group of the nucleotide of the 3' hydroxyl of the oligonucleotide or polynucleotide and the phosphodiester bond between the 3' carbon atom of the oligonucleotide or polynucleotide and the 5' carbon atom of the nucleotide as described herein.
[0147] As used herein, the term "cleavable linker" is not intended to imply that the entire linker needs to be removed. The cleavage site can be located at a position on the linker that ensures that a portion of the linker remains attached to the detectable label and / or nucleoside or nucleotide moiety after cleavage.
[0148] As used herein, "derivative" or "analog" means a synthetic nucleotide or nucleoside derivative with a modified base moiety and / or a modified sugar moiety. Such derivatives and analogs are discussed in, for example, Scheit, Nucleotide Analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90: 543-584, 1990. Nucleotide analogs can also include modified phosphodiester bonds, including phosphorothioate bonds, phosphorodithioate bonds, alkylphosphonate bonds, aniline phosphate bonds and phosphoramidate bonds. As used herein, "derivative", "analog" and "modified" can be used interchangeably, and are covered by the terms "nucleotide" and "nucleoside" defined herein.
[0149] As used herein, the term "phosphate" is used with the ordinary meaning understood by those skilled in the art and includes its protonated form (e.g., ). As used herein, the terms "monophosphate," "diphosphate," and "triphosphate" are used with their ordinary meaning as understood by those skilled in the art, and include protonated forms.
[0150] As used herein, the term "protecting group" refers to any atom or group of atoms added to a molecule in order to prevent existing groups in the molecule from undergoing undesired chemical reactions. Sometimes, "protecting group" and "capping group" are used interchangeably.
[0151] As used herein, the term "phasing" refers to a phenomenon in SBS, which is caused by the incomplete removal of 3' terminators and fluorophores and the failure to complete the incorporation of a portion of the DNA chain in the cluster by a polymerase under a given sequencing cycle. Prephasing is caused by the incorporation of nucleotides that do not have an effective 3' terminator, wherein the incorporation event is advanced by 1 cycle due to termination failure. Phasing and prephasing cause the measured signal intensity of a specific cycle to be composed of the signal from the current cycle and the noise from the previous and next cycles. As the number of cycles increases, the sequence score of each cluster affected by phasing and prephasing increases, hindering the identification of the correct base. Prephasing can be caused by the presence of trace amounts of unprotected or uncapped 3'-OH nucleotides during sequencing by synthesis (SBS). Unprotected 3'-OH nucleotides can be produced during the manufacturing process or may be produced during storage and reagent handling processes. Therefore, the discovery of nucleotide analogs that reduce the incidence of prephasing is surprising and provides greater advantages than existing nucleotide analogs in SBS applications. For example, the provided nucleotide analogs can lead to faster SBS cycle times, lower phasing and prephasing values, and longer sequencing read lengths.
[0152] Sequencing method using nucleotides having 3' allyl blocking groups
[0153] Some embodiments of the present disclosure relate to a method of determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising:
[0154] (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein:
[0155] (i) the solid support comprises a plurality of different target polynucleotides; and
[0156] (ii) the sequencing primer is complementary to at least a portion of the different target polynucleotide;
[0157] (b) contacting the solid support with an aqueous solution comprising a DNA polymerase and nucleotides A, G, C and T or U (e.g., dATP, dCTP, dGTP and dTTP or dUTP) under conditions suitable for DNA polymerase-mediated primer extension, wherein each nucleotide comprises a 3′ allyl capping group attached to a 3′ oxygen atom The 2′ deoxyribose moiety;
[0158] (c) imaging the solid support to determine the identity of the incorporated nucleotide (e.g., by performing one or more fluorescence measurements of the extended copy polynucleotide to determine the identity of the incorporated nucleotide);
[0159] (d) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine in an aqueous solution suitable for chemically removing the 3'-allyl blocking group from the incorporated nucleotide to expose the 3'-
[0160] contacting the OH groups under conditions for further nucleotide incorporation on the solid support;
[0161] (e) contacting the solid support with an aqueous washing solution; and
[0162] (f) repeating steps (b) to (e) to determine the target polynucleotide sequence. In some embodiments of the methods described herein, the aqueous solution comprising the DNA polymerase in step (b) further comprises a palladium scavenger. In other embodiments, the palladium scavenger in step (b) is a Pd(0) scavenger described herein. In some embodiments, the aqueous wash solution in step (e) further comprises a palladium scavenger. In other embodiments, the palladium scavenger in step (e) is a Pd(II) scavenger described herein. In other embodiments, the aqueous deblocking solution further comprises an ascorbate, such as sodium ascorbate. In some embodiments, the solid support comprises at least 500,000, 1,000,000, 2,000,000,
[0163] 3,000,000, 4,000,000 or 5,000,000 spatially distinguishable sites / cm 2 ,
[0164] The site contains multiple copies of the target polynucleotide.
[0165] In some embodiments of the methods described herein, at least one type of nucleotide comprises a base attached to a detectable label via a cleavable linker. In other embodiments, the cleavable linker comprises a moiety selected from the group consisting of:
[0166] and * indicates the position where this portion is attached to the rest of the nucleotides. In other embodiments, the cleavable linker is
[0167] In some other embodiments, the detectable label is a fluorescent dye and the cleavable linker is selected from the group consisting of:
[0168]
[0169]
[0170] wherein Z is -O-CH2-CH=CH2; n is an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the base; and ** indicates the point of attachment of the cleavable linker to the detectable label. In another embodiment, when the nucleotide is a T nucleotide, the cleavable linker is connected via In other embodiments, when the nucleotide is a T nucleotide, the cleavable linker is In some embodiments of the methods described herein, at least three types of nucleotides comprise a nucleobase attached to a detectable label via a cleavable linker. In one embodiment, each of the A, C, and T nucleotides comprises a nucleobase attached to a detectable label via a cleavable linker described herein. In other embodiments, the detectable label of each type of at least three types of nucleotides is distinguishable from the other detectable labels, and the cleavable linker is selected from the group consisting of:
[0171]
[0172] wherein Z is -O-CH2-CH=CH2; n is an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the base; and ** indicates the point of attachment of the cleavable linker to the detectable label. In other embodiments, each of the four types of nucleotides is unlabeled.
[0173] Some other embodiments of the present disclosure relate to a method of determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising:
[0174] (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein:
[0175] (i) the solid support comprises a plurality of different target polynucleotides; and
[0176] (ii) the sequencing primer is complementary to at least a portion of the different target polynucleotide;
[0177] (b) contacting the solid support with an aqueous solution comprising a DNA polymerase and nucleotides A, G, C and T or U (e.g., dATP, dCTP, dGTP and dTTP or dUTP) under conditions suitable for DNA polymerase-mediated primer extension, wherein:
[0178] (i) each of the at least three types of nucleotides independently comprises a base attached to a detectable label via a cleavable linker, and the cleavable linker comprises a moiety selected from the group consisting of:
[0179] and * indicates the position where this portion is attached to the rest of the nucleotides;
[0180] (ii) each nucleotide comprises a 3′ allyl group attached to the 3′ oxygen atom The 2′ deoxyribose moiety of
[0181] (iii) the DNA polymerase is an altered archaeal DNA polymerase;
[0182] (c) contacting the solid support with a solution comprising one or more free radical scavengers, and imaging the solid support to determine the identity of the incorporated nucleotide (e.g., by performing one or more fluorescence measurements of the extended copy polynucleotide to determine the identity of the incorporated nucleotide);
[0183] (d) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for (i) chemically removing the 3'-allyl blocking group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support; and (ii) chemically removing the detectable label attached via the cleavable linker;
[0184] (e) contacting the solid support with an aqueous wash solution comprising a palladium scavenger; and
[0185] (f) repeating steps (b) to (e) to determine the target polynucleotide sequence. In some embodiments, the palladium scavenger in the aqueous washing solution of step (e) is a Pd(II) scavenger described herein. In other embodiments, the aqueous solution comprising a DNA polymerase in step (b) further comprises a palladium scavenger. In some such embodiments, the palladium scavenger in step (b) is a Pd(0) scavenger described herein. In some embodiments, the solid support comprises at least 500,000, 1,000,000, 2,000,000, 3,000,000, 4,000,000 or 5,000,000 spatially distinguishable sites / cm 2 , the site contains multiple copies of the target polynucleotide.
[0186] Some additional embodiments of the present disclosure relate to a method of determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising:
[0187] (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein:
[0188] (i) the solid support comprises a plurality of different target polynucleotides; and
[0189] (ii) the sequencing primer is complementary to at least a portion of the different target polynucleotide;
[0190] (b) contacting the solid support with an aqueous solution comprising a DNA polymerase and nucleotides A, G, C and T or U (e.g., dATP, dCTP, dGTP and dTTP or dUTP) under conditions suitable for DNA polymerase-mediated primer extension, wherein:
[0191] (i) at least one of the nucleotides comprises a base attached to a detectable label via a cleavable linker; and
[0192] (ii) the nucleotides each comprise a 3′ allyl capping group having a 3′ allyl group attached to the 3′ oxygen atom
[0193] The 2′ deoxyribose moiety;
[0194] (c) contacting the solid support with a solution comprising one or more free radical scavengers, and imaging the solid support to determine the identity of the incorporated nucleotide (e.g., by performing one or more fluorescence measurements of the extended copy polynucleotide to determine the identity of the incorporated nucleotide);
[0195] (d) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for (i) chemically removing the 3'-allyl group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support; and (ii) chemically removing the detectable label attached via the cleavable linker;
[0196] (e) contacting the solid support with an aqueous washing solution; and
[0197] (f) repeating steps (b) to (e) to determine the target polynucleotide sequence. In some embodiments, the aqueous wash solution in step (e) further comprises a palladium scavenger. In some embodiments, the solid support comprises at least 500,000, 1,000,000, 2,000,000, 3,000,000,
[0198] 4,000,000 or 5,000,000 spatially distinguishable sites / cm 2 , the site comprises multiple copies of the target polynucleotide. In some such embodiments, the palladium scavenger in the aqueous washing solution of step (e) is a Pd(II) scavenger described herein. In some other embodiments, the aqueous solution comprising the DNA polymerase in step (b) further comprises a palladium scavenger. In some such embodiments, the palladium scavenger in step (b) is a Pd(0) scavenger described herein.
[0199] Post-incorporation labeling SBS workflow
[0200] Another aspect of the present disclosure relates to an alternative sequencing-by-synthesis method, wherein at least one labeling agent is introduced after incorporation of unlabeled nucleotides. In particular, the present disclosure relates to a method for determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising:
[0201] (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein:
[0202] (i) the solid support comprises at least 5,000,000 spatially distinguishable sites
[0203] / cm 2 , the site comprises multiple copies of the target polynucleotide;
[0204] (ii) the solid support comprises a plurality of different target polynucleotides; and
[0205] (iii) the sequencing primer is complementary to at least a portion of the different target polynucleotide;
[0206] (b) contacting the solid support with an aqueous spike-in mixture comprising a DNA polymerase and one or more of the four types of nucleotides A, G, C and T or U under conditions suitable for DNA polymerase-mediated primer extension, wherein:
[0207] (i) the nucleotides each comprise a 3′ allyl capping group attached to the 3′ oxygen atom
[0208] The 2′ deoxyribose moiety;
[0209] (ii) at least one type of nucleotide is unlabeled; and
[0210] (iii) a first type of unlabeled nucleotide comprising a first functional moiety;
[0211] (c) contacting the extended copy polynucleotide with an aqueous labeling mixture comprising a first labeling reagent, wherein the first labeling reagent comprises one or more first detectable labels and a first binding portion capable of specifically binding to a first functional portion of a first type of unlabeled nucleotide;
[0212] (d) imaging the solid support and performing one or more fluorescence measurements (i.e., to determine the identity of the incorporated nucleotide);
[0213] (e) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for (i) chemically removing the 3'allyl group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support;
[0214] (f) contacting the solid support with an aqueous washing solution; and
[0215] (g) repeating steps (b) to (f) to determine the target polynucleotide sequence. In some embodiments, at least two types of nucleotides are unlabeled.
[0216] In some embodiments, step (c) is performed under conditions where the first labeling agent specifically binds to the incorporated unlabeled first type of nucleotides to provide a labeled extended copy polynucleotide. In some embodiments, the first functional portion of the first type of unlabeled nucleotides is bound to the first labeling agent by covalent binding (optionally via a cleavable linker as described herein). In some other embodiments, the first functional portion of the first type of unlabeled nucleotides is bound to the first labeling agent by non-covalent interactions (optionally via a cleavable linker as described herein).
[0217] In some embodiments, each of the four types of nucleotides in the aqueous incorporation mixture is unlabeled, and the unlabeled nucleotides of the second type include a second functional portion, wherein the aqueous labeling mixture includes a second labeling agent, and the second labeling agent includes one or more third detectable labels and a second binding portion that can specifically bind to the second functional portion of the unlabeled nucleotides of the second type. In some such embodiments, step (c) is performed under conditions where the first labeling agent specifically binds to the unlabeled first type of nucleotides incorporated, and the second labeling agent specifically binds to the unlabeled second type of nucleotides incorporated to provide a labeled extended copy polynucleotide. In some such embodiments, the first functional portion of the unlabeled nucleotides of the first type is bound to the first labeling agent by covalent binding (optionally via a cleavable linker as described herein). In some other embodiments, the second functional portion of the unlabeled nucleotides of the first type is bound to the second labeling agent by non-covalent interactions (optionally via a cleavable linker as described herein). In some such embodiments, the third type of unlabeled nucleotides comprises a third functional portion, wherein the aqueous labeling mixture comprises a third labeling agent, and the third labeling agent comprises one or more third detectable labels and a third binding portion capable of specifically binding to the third functional portion of the third type of unlabeled nucleotides. In some such embodiments, step (c) is performed under conditions in which the first labeling agent specifically binds to the incorporated unlabeled first type of nucleotides, the second labeling agent specifically binds to the incorporated unlabeled second type of nucleotides, and the third labeling agent specifically binds to the incorporated unlabeled third type of nucleotides to provide a labeled extended copy polynucleotide. In some other embodiments, the third type of unlabeled nucleotides comprises a mixture of the third type of unlabeled nucleotides containing the first functional portion and the third type of unlabeled nucleotides containing the second functional portion, and wherein both the first labeling agent and the second labeling agent are capable of specifically binding to the third type of unlabeled nucleotides.
[0218] In any of the embodiments of the post-incorporation labeling methods described herein, the fourth type of unlabeled nucleotide is incapable of specifically binding to any of the first labeling agent, the second labeling agent, or the third labeling agent.
[0219] In some embodiments of the post-incorporation labeling methods described herein, the T nucleotide has the following structure: In other embodiments, the T nucleotide has the following structure: In other embodiments, the T nucleotide has the following structure: wherein Z is -O-CH2-CH=CH2, and each of m and n is independently an integer of 1, 2, 3, 4 or 5.
[0220] In some embodiments of the post-incorporation labeling methods described herein, the C nucleotide has the following structure: In other embodiments, the C nucleotide has the following structure: In other embodiments, the C nucleotide has the following structure: wherein Z is -O-CH2-CH=CH2, and each of m and n is independently an integer of 1, 2, 3, 4 or 5.
[0221] In some embodiments of the post-incorporation labeling methods described herein, the A nucleotide has the following structure: In other embodiments, the A nucleotide has the following structure: In other embodiments, the A nucleotide has the following structure: wherein Z is -O-CH2-CH=CH2, and each of m and n is independently an integer of 1, 2, 3, 4 or 5. In other embodiments, the A nucleotide has the following structure: In other embodiments, the A nucleotide has the following structure: In other embodiments, the A nucleotide has the following structure: wherein Z is -O-CH2-CH=CH2, and each of m and n is independently an integer of 1, 2, 3, 4 or 5.
[0222] In some embodiments, the G nucleotide is unlabeled. In other embodiments, the G nucleotide has a structure selected from the group consisting of:
[0223]
[0224] Other examples of connectors are disclosed in U.S. Patent Publication No. 2020 / 0216891A1, which is incorporated by reference in its entirety:
[0225]
[0226]
[0227] Wherein B is a nucleobase; n is 1, 2, 3, 4, 5; k is 1; Z is -N3 (azido), -O-C1-C6 alkyl, -O-C2-C6 alkenyl or -O-C2-C6 alkynyl; and R comprises a detectable label or binding moiety for post-incorporation labeling, which may contain additional linkers and / or spacer structures. One of ordinary skill in the art understands that the detectable label or binding moiety described herein is covalently bound to the linker by reacting a functional group (e.g., carboxyl) of the compound containing the binding moiety with a functional group (e.g., amino) of the linker to form an amide bond. In one embodiment, the cleavable linker comprises ("AOL" linker moiety), wherein Z is -O-allyl. For purposes of this disclosure, a nucleotide may contain multiple cleavable linker repeating units (eg, k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
[0228] In certain embodiments, the unlabeled nucleotides may be enzymatically incorporable and enzymatically extendable. Thus, the linker portion may have a sufficient length to connect the nucleotide to the compound so that the compound does not significantly interfere with the overall binding and recognition of the nucleotide by the nucleic acid replicating enzyme. Thus, the linker may also include a spacer unit, such as one or more PEG units (-OCH2CH2-) n , wherein n is an integer from 1 to 20, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15. The spacer distance is, for example, the distance in nucleotide bases from the cleavage site or label.
[0229] In some embodiments of any of the methods described herein, the solid support is contacted with the deblocking solution for about 1 second to 20 seconds, about 2 seconds to 10 seconds, about 3 seconds to 8 seconds, or about 4 seconds to 5 seconds. For example, the solid support is contacted with the deblocking solution of step (d) or step (e) for about 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, 6 seconds, 7 seconds, 8 seconds, 9 seconds, 10 seconds, 11 seconds, 12 seconds, 13 seconds, 14 seconds, 15 seconds, 16 seconds, 17 seconds, 18 seconds, 19 seconds or 20 seconds, or a range limited by any two of the aforementioned values. In other embodiments, the solid support is contacted with the deblocking solution via continuous flow without pausing incubation.
[0230] In some embodiments of any of the methods described herein, the sequencing cycles (e.g., steps (b) to (e) or steps (b) to (f)) are repeated at least about 20 times, 30 times, or 50 times. In other embodiments, steps (b) to (e) or steps (b) to (f) are repeated at least about 100 times, 150 times, 200 times, 250 times, 300 times, 350 times, 400 times, 450 times, or 500 times. In some embodiments, after about 50 repetition cycles, the prephasing value is less than 0.18. In some embodiments, after about 50 repetition cycles, the phasing value is less than 0.18. In other embodiments, after about 50 repetition cycles, the prephasing or phasing value is less than 0.07. In other embodiments, after about 100 repetition cycles, the prephasing value is less than 0.10 and the phasing value is less than 0.10. In other embodiments, after about 150 repetitive cycles, the prephase value is less than 0.25 and the phasing value is less than 0.25. In other embodiments, after about 150 repetitive cycles, the prephase value is less than 0.2 and the phasing value is less than 0.2. In other embodiments, after about 150 repetitive cycles, the prephase value is less than 0.15 and the phasing value is less than 0.15. In other embodiments, after about 150 repetitive cycles, the prephase value is less than 0.1 and the phasing value is less than 0.1.
[0231] In some embodiments of any of the methods described herein, the DNA polymerase is an altered family B archaeal DNA polymerase comprising a 3-amino acid region that is functionally equivalent or homologous to amino acids 408 to 410 in 9°N DNA polymerase, wherein the first amino acid of the 3-amino acid region is an amino acid selected from the group consisting of isoleucine (I), alanine (A), valine (V), and serine (S); the second amino acid of the 3-amino acid region is an amino acid selected from the group consisting of alanine (A) and glycine (G); and the third amino acid of the 3-amino acid region is an amino acid selected from the group consisting of alanine (A), isoleucine (I), valine (V), leucine (L), threonine (T), and proline (P).
[0232] Palladium catalyst
[0233] In some embodiments of any of the methods described herein, the Pd catalyst used to remove or cleave the 3'allyl end-capping groups described herein is water soluble. In some such embodiments, the Pd catalyst is in the form of an active Pd(0). In some cases, the Pd(0) catalyst can be generated in situ by reduction of a Pd complex or a Pd precatalyst (e.g., a Pd(II) complex) with a reagent such as an olefin, an alcohol, an amine, a phosphine, or a metal hydride. Suitable Pd sources include Pd(CH3CN)2Cl2, [Pd(allyl)Cl]2, [Pd(allyl)(THPP)]Cl, [Pd(allyl)(THPP)2]Cl, Na2PdCl4, K2PdCl4, Li2PdCl4, Pd(OAc)2, Pd(PPh3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), Pd(TFA)2, Na2PdBr4, K2PdBr4, PdCl2, PdBr2, and Pd(NO3)2. In one such embodiment, the Pd(0) complex is generated in situ from an organic or inorganic salt of palladium(II) salt, such as Na2PdCl4 or K2PdCl4. In another embodiment, the palladium source is allylpalladium(II) chloride dimer [(allyl)PdCl]2 or [PdCl(C3H5)]2. In some embodiments, the Pd(0) catalyst is generated in aqueous solution by mixing a Pd(II) complex with a water-soluble phosphine, such as a tris(hydroxyalkyl)phosphine. Suitable tris(hydroxyalkyl)phosphines include tris(hydroxypropyl)phosphine (THPP), tris(hydroxymethyl)phosphine (THMP), or tris(hydroxyethyl)phosphine (THEP), or a combination thereof. In one embodiment, the water-soluble phosphine is THPP.
[0234] In some embodiments, the palladium catalyst is prepared by mixing [(allyl)PdCl]2 with THP in situ. The molar ratio of [(allyl)PdCl]2 and THP can be about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5, or 1:10. In one embodiment, the molar ratio of [(allyl)PdCl]2 and THP is 1:10. In some other embodiments, the palladium catalyst is prepared by mixing a water-soluble Pd reagent such as Na2PdCl4 or K2PdCl4 with THP in situ. The molar ratio of Na2PdCl4 or K2PdCl4 to THP may be about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5, or 1:10. In one embodiment, the molar ratio of Na2PdCl4 or K2PdCl4 to THP is about 1:3. In another embodiment, the molar ratio of Na2PdCl4 or K2PdCl4 to THP is about 1:3.5. In yet another embodiment, the molar ratio of Na2PdCl4 or K2PdCl4 to THP is about 1:2.5.
[0235] The Pd complex and water-soluble phosphine used in the cleavage step of the method described herein can be in a composition or mixture, also referred to as a cleavage mixture. In other embodiments, the cleavage mixture may contain one or more reducing agents, such as ascorbic acid or a salt thereof (e.g., sodium ascorbate) or a boron-containing reducing agent. In other embodiments, the cleavage mixture may contain one or more buffer reagents, such as primary amines, secondary amines, tertiary amines, natural amino acids, non-natural amino acids, carbonates, phosphates, or borates, or combinations thereof. In other embodiments, the buffer reagent includes ethanolamine (EA), tris (hydroxymethyl) aminomethane (Tris), glycine, sodium carbonate, sodium phosphate, sodium borate, dimethylethanolamine (DMEA), diethylethanolamine (DEEA), N,N,N′,N′-tetramethylethylenediamine (TMEDA), N,N,N′,N′-tetraethylethylenediamine (TEEDA), or 2-piperidineethanol (also referred to as (2-hydroxyethyl) piperidine, which has the following structure: ) or a combination thereof. In one embodiment, one or more buffer reagents include DEEA. In another embodiment, one or more buffer reagents include (2-hydroxyethyl) piperidine. In another embodiment, one or more buffer reagents contain one or more inorganic salts, such as carbonate, phosphate or borate, or a combination thereof. In one embodiment, the inorganic salt is a sodium salt.
[0236] reducing agent
[0237] According to the present disclosure, a reducing agent can be used to promote the formation of Pd(0) active species for 3' deblocking reaction and / or cleavage of the joint. In some embodiments, the reducing agent contains boron. For example, the reducing agent can be a borane, a disubstituted boronic acid, a boric acid, a boric ester or a borohydride. In some embodiments, the reducing agent is a borane or a boric acid. Suitable boranes include diborane, triborane, tetraborane, pentaborane, hexaborane, heptaborane, octaborane, nonaborane, decaborane, borane tetrahydrofuran, borane dimethyl sulfide, catechol borane, dichlorophenyl borane, borane diphenylphosphine complex, dicyclohexyl iodide borane, bromodimethyl borane, diethyl methoxy borane, dichloromethyl diisopropoxy borane, bromodimethyl borane and monobromo borane methyl sulfide. Suitable boranes include amino-boranes. Suitable amine-boranes include pyridine-borane, N-heteroaromatic-borane complexes, ammine borohydride (NH3BH3), borane-ammine complexes, borane dimethylamine, borane tert-butylamine, borane trimethylamine, borane isopropylamine, dichloro (diisopropylamino) borane and cycloborazine. Suitable boric acids include boric acid, 4-hydroxyphenylboric acid, tetrahydroxydiboron (B2(OH)4), phenylboric acid, 2-thienylboronic acid, methylboric acid, cis-propenylboric acid and trans-propenylboric acid. Suitable boric acid esters include allylboronic acid pinacol ester, phenylboronic acid propylene glycol ester and diisopropoxymethylborane. Suitable borohydrides include sodium borohydride (Na2BH4), lithium borohydride, calcium borohydride, calcium bis(tetrahydrofuran)borohydride, magnesium borohydride, potassium borohydride, potassium triethylborohydride, sodium triacetoxyborohydride, tetraethylammonium borohydride, and tetrabutylammonium borohydride. In some embodiments, the concentration of the reducing agent (such as a boron-containing reducing agent) in the first aqueous solution (also referred to as the cleavage mixture) is about 0.1mM, 0.2mM, 0.3,mM, 0.4mM, 0.5mM, 0.6mM, 0.7mM, 0.8mM, 0.9mM, 1mM, 1.5mM, 2mM, 2.5mM, 3mM, 3.5mM, 4mM, 4.5mM, 5mM, 5.5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, 16mM, 17mM, 18mM, 19mM, 20mM, 21mM, 22mM, 23mM, 24mM, 25mM, 26mM, 27mM, 28mM, 29mM, 30mM, 31mM, 32mM, 33mM, 34mM, 35mM, 36mM, 37mM, 38mM, 39mM, 40mM, 41mM, 42mM, 43mM, 44mM, 45mM, 46mM, 47mM, 48 7mM, 8mM, 9mM, 9.5mM, 10mM, 12.5mM, 15mM, 17.5mM, 20mM, 22.5mM, 25mM, 37.5mM, 30mM, 35mM, 40mM, 45mM, 50mM, 55mM, 60mM, 65mM, 70mM or 75mM, or a range bounded by any two of the preceding values.
[0238] In some embodiments, the cleavage conditions of the 3' blocking group are the same as the conditions for cleaving the cleavable linker of the nucleotide. For example, the nucleotide can include the same linker portion as the 3' blocking group. In other embodiments, the cleavage conditions of the 3' blocking group are different from the conditions for cleaving the cleavable linker of the nucleotide.
[0239] Palladium scavenger
[0240] Pd(0) scavenger
[0241] Certain aspects of the present disclosure relate to the use of alternative palladium scavengers in several steps of sequencing by synthesis, wherein at least one palladium scavenger comprises one or more allylic moieties, such as -O-allyl, -S-allyl, -NR-allyl, or -N-allyl. + RR′-allyl or a combination thereof, wherein R is H, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C2-C6 alkenyl, unsubstituted or substituted C2-C6 alkynyl, unsubstituted or substituted C6-C 10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C3-C 10 carbocyclyl, or unsubstituted or substituted 5- to 10-membered heterocyclyl; and R′ is H, unsubstituted C1-C6 alkyl or substituted C1-C6 alkyl.
[0242] Allyl-containing Pd scavengers act as competitive substrates to consume any residual Pd(0) attached to nucleic acids (i.e., Pd(0) scavengers). These palladium scavengers are described in WO 2022 / 243480, which is incorporated by reference in its entirety. The sequencing methods described herein substantially improve sequencing metrics (e.g., reducing phasing values and prephasing values) and can also reduce sequencing time per cycle by eliminating certain post-cleavage processing steps.
[0243] In some embodiments of any of the methods described herein, a Pd(0) scavenger comprising one or more allyl moieties is in an aqueous solution containing a DNA polymerase and nucleotides. In some cases, the aqueous solution in step (b) is also referred to as an incorporation mixture (IMX). In some such embodiments, such palladium scavengers are compatible with other sequencing reagents incorporated into the mixture, which may include a polymerase (such as a DNA polymerase) in addition to one or more different types of nucleotides. In some such embodiments, the polymerase is a DNA polymerase, such as a mutant of a 9°N polymerase (e.g., those disclosed in WO 2005 / 024010, which is incorporated by reference), e.g., Pol 812, Pol 1901, Pol 1558, or Pol 963. The amino acid sequences of Pol 812, Pol1901, Pol 1558 or Pol 963 DNA polymerases are described in, for example, U.S. Patent Publication Nos. 2020 / 0131484A1 and 2020 / 0181587A1, which are incorporated herein by reference. In some embodiments, the incorporation mixture further comprises one or more buffers. The buffer may include primary amines, secondary amines, tertiary amines, natural amino acids or non-natural amino acids, or a combination thereof. In another embodiment, the buffer includes ethanolamine or glycine, or a combination thereof. In one embodiment, the buffer includes glycine, or is glycine. In another embodiment, a palladium scavenger comprising one or more allyl moieties does not require a separate washing step before the next incorporation cycle. In another embodiment, the palladium scavenger incorporated into the mixture is a Pd(0) scavenger as described herein. In some embodiments, the Pd(0) scavenger is premixed with one or more of the DNA polymerase and / or four types of nucleotides (e.g., dATP, dCTP, dGTP and dTTP or dUTP). In other embodiments, the Pd(0) scavenger is stored separately from the DNA polymerase and / or one or more of the four types of nucleotides and is mixed with these components shortly before the start of the sequencing run.
[0244] In some embodiments of any of the methods described herein, the concentration of the Pd(0) scavenger comprising one or more allyl moieties in an aqueous solution containing a DNA polymerase and nucleotides (e.g., A, G, C, and T or U; or dATP, dCTP, dGTP, and dTTP or dUTP) is from about 0.1 mM to about 100 mM, from about 0.2 mM to about 75 mM, from about 0.5 mM to about 50 mM, from about 1 mM to about 20 mM, or from about 2 mM to about 10 mM. In other embodiments, the concentration of the palladium scavenger (e.g., Pd(0) scavenger) is about 0.1 mM, 0.2 mM, 0.3 mM, 0.4 mM, 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1 mM, 1.5 mM, 2 mM, 2.5 mM, 3 mM, 3.5 mM, 4 mM, 4.5 mM, 5 mM, 5.5 mM, 6 mM, 6.5 mM, 7 mM, 7.5 mM, 8 mM, 8.5 mM, 9 mM, 9.5 mM, 10 mM, 12.5 mM, 15 mM, 17.5 mM, or 20 mM, or a range defined by any two of the foregoing values. In other embodiments, the concentration of such palladium scavenger is the concentration in the admixture. In other embodiments, the pH of the admixture is about 9.
[0245] In some other embodiments of any of the methods described herein, a Pd(0) scavenger comprising one or more allyl moieties is in solution when performing one or more fluorescence measurements. In such embodiments, such palladium scavengers are compatible with the sequencing reagents of the scanning solution (also referred to as the scanning mixture). In further embodiments, the one or more palladium scavengers do not require a separate washing step prior to the next incorporation cycle. In further embodiments, the palladium scavenger in the scanning solution is a Pd(0) scavenger described herein.
[0246] In other embodiments of the methods described herein, a Pd(0) scavenger comprising one or more allyl moieties is in the post-cleavage wash solution. In additional embodiments, the palladium scavenger in the post-cleavage wash solution is a Pd(0) scavenger described herein. In some such embodiments, the post-cleavage wash solution does not comprise lipoic acid or 3,3′-dithiodipropionic acid (DDPA).
[0247] In yet other embodiments of the methods described herein, a Pd(0) scavenger comprising one or more allyl moieties may be present in both the spiked mixture and the post-cleavage wash solution, or in both the spiked mixture and the scanned mixture. In some such embodiments, the post-cleavage wash solution does not comprise lipoic acid or DDPA.
[0248] Non-limiting examples of Pd(0) scavengers comprising one or more -O-allyl or allylic moieties include the following:
[0249] (Compound A), (Compound B, N-BocTyr(allyl)-OH), (Compound C, allyl-β-D-glucopyranoside), (Compound D), (Compound E),
[0250] (Compound F), (Compound G),
[0251] (Compound H), (Compound I), (Compound J), (Compound K), (Compound L),
[0252] (Compound M) and (Compound N).
[0253] Non-limiting examples of Pd(0) scavengers comprising one or more -S-allyl moieties include the following:
[0254] Contains one or more –NR-allyl or –N + Non-limiting examples of RR'-allyl moieties of Pd(0) scavengers include the following: Where Z ˉ is an anion (e.g., a halide anion such as F ˉ or Cl ˉ In one embodiment, the palladium scavenger is Cl ˉ (Compound O, diallyldimethylammonium chloride, also known as DADMAC).
[0255] Pd(II) Scavengers
[0256] In some embodiments of the methods described herein, the method may further use an additional palladium scavenger, such as a Pd (II) scavenger. In some such embodiments, the use of an additional Pd (II) scavenger can improve the phasing value of the sequencing index. For example, the Pd (II) scavenger may include isocyanoacetic acid (ICNA) salts, ethyl isocyanoacetate, methyl isocyanoacetate, cysteine (e.g., L-cysteine) or its salt (e.g., N-acetyl-L-cysteine), potassium ethyl xanthate, potassium isopropyl xanthate, glutathione, ethylenediaminetetraacetic acid (EDTA), iminodiacetic acid, nitrilodiacetic acid, trithio-S-triazine, dimethyl dithiocarbamate, dithiothreitol, mercaptoethanol, allyl alcohol, propargyl alcohol, thiol, thiosulfate (e.g., sodium thiosulfate or potassium thiosulfate), tertiary amines and / or tertiary phosphines or combinations thereof. In one embodiment, the method further includes the use of L-cysteine or its salt. In another embodiment, the method further comprises using thiosulfate such as sodium thiosulfate (Na2S2O3). In some such embodiments, Pd (II) scavenger (e.g., L-cysteine or sodium thiosulfate) is in an aqueous solution (i.e., incorporation mixture) containing DNA polymerase and nucleotides. In other embodiments, Pd (II) scavenger (e.g., L-cysteine or sodium thiosulfate) is in a post-cleavage washing solution. In other embodiments, Pd (II) scavenger (e.g., L-cysteine or sodium thiosulfate) may all be present in the incorporation mixture. In other embodiments, Pd (II) scavenger (e.g., L-cysteine or sodium thiosulfate) may be present in a scanning mixture (i.e., a solution in which one or more fluorescence measurements of the incorporated nucleotides are performed). In other embodiments, Pd (II) scavenger may be present in one or more of the incorporation mixture (i.e., the aqueous solution of step (b)), the scanning mixture, or the post-cleavage washing solution (i.e., the aqueous solution of step (e)). In other embodiments, the concentration of the Pd(II) scavenger (such as L-cysteine or sodium thiosulfate) in the incorporation mixture or post-lysis wash solution is about 0.1 mM to about 100 mM, 0.2 mM to about 75 mM, about 0.5 mM to about 50 mM, about 1 mM to about 20 mM, or about 2 mM to about 10 mM. In other embodiments, the concentration of the Pd(II) scavenger (such as L-cysteine or sodium thiosulfate) is about 0.1 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 6.5 mM, 7 mM, 8 mM, 9 mM, 10 mM, 12.5 mM, 15 mM, 17.5 mM or 20 mM, or a range defined by any two of the foregoing values. In further embodiments, the Pd(II) scavenger is in the post-lysis wash solution, and the concentration of the Pd(II) scavenger in the post-lysis wash solution is about 10 mM.In additional embodiments, the post-lysis wash solution does not contain lipoic acid or DDPA. In other embodiments, the method does not include a post-lysis wash step.
[0257] In some embodiments of the methods described herein, the target polynucleotide is fixed to the surface of a substrate or a solid support. In other embodiments, the surface comprises a variety of fixed target polynucleotides, such as arrays of different fixed target polynucleotides. In some such embodiments, the substrate or solid support includes glass, modified or functionalized glass, plastic, polysaccharide, nylon, nitrocellulose, resin, silica, silicon, modified silicon, carbon, metal, inorganic glass or fiber bundle or a combination thereof. In other embodiments, the substrate is a flow cell, nanoparticles or beads (such as spherical silica beads, inorganic nanoparticles, magnetic nanoparticles, cadmium base points and cadmium-free points, or beads disclosed in U.S. Publication No. 2021 / 0187470A1, which are incorporated by reference). In one embodiment, the substrate or solid support is a flow cell including a patterned nanopore separated by a gap region, and wherein the fixed target polynucleotide resides in the patterned nanopore. In some embodiments, the substrate or solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises a concatemer comprising multiple copies of the target polynucleotide. In some other embodiments, the substrate or solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises a fixed nucleic acid molecule cluster, and the fixed nucleic acid molecule cluster comprises multiple copies of the target polynucleotide.
[0258] In some embodiments of any of the methods described herein, the method is performed on an automatic sequencing instrument, and wherein the automatic sequencing instrument comprises two light sources operating at different wavelengths (e.g., about 450 nm to about 460 nm, and about 520 nm to about 540 nm, in particular about 460 nm and about 532 nm). In other embodiments, the automatic sequencing instrument comprises a single light source operating at one wavelength.
[0259] Nucleotides with 3' allyl end capping group
[0260] Some embodiments of the present disclosure relate to nucleotide molecules comprising a nucleobase, a ribose or deoxyribose moiety and a 3' capping group comprising an unsubstituted or substituted allyl moiety. In one embodiment, the 3' capping group is an allyl group (-CH2CH=CH2) attached to the 3' oxygen atom of the deoxyribose moiety. In some embodiments, the nucleotide is unlabeled. In other embodiments, the nucleotide is a labeled nucleotide as described herein. In some embodiments, the bases of A and G nucleotides are deazapurines (e.g., 7-deazapurines, such as 7-deazaadenine or 7-deazaguanine). In some other embodiments, at least one type of nucleotide used in any of the sequencing methods described herein has a structure selected from the group consisting of:
[0261]
[0262] In further embodiments, at least one type of nucleotide has a structure selected from the group consisting of:
[0263]
[0264] Labeled nucleotides
[0265] In some embodiments, the nucleotide of 3' block also includes a detectable label, and this nucleotide is referred to as a labeled nucleotide or a fully functionalized nucleotide (ffN). Labels (e.g., fluorescent dyes) are conjugated via a cleavable joint in a variety of ways, and these ways include hydrophobic attraction, ion attraction, and covalent bonding. In some aspects, dyes are conjugated to nucleotides by covalent bonding realized via a cleavable joint. One of ordinary skill in the art understands that the label can be covalently bound to a joint by reacting the functional group (e.g., carboxyl) of the label with the functional group (e.g., amino) of the joint. In some such embodiments, a cleavable joint can include the same part as the 3' blocking group. Therefore, cleavable joints and 3' blocking groups can be cracked or removed under the same reaction conditions. In some such embodiments, a cleavable joint can include an allyl moiety, specifically a part including the following structure:
[0266] Where R 1a , R 1b , R 2a , R 3a and R 3b Each is independently H, halogen, unsubstituted or substituted C1-C6 alkyl or C1-C6 haloalkyl. In another embodiment, R 1a , R 1b , R 2a , R 3aand R 3b Each is H.
[0267] In some embodiments, the detectable label can be covalently attached to the oligonucleotide or nucleotide via a nucleotide base. For example, a labeled nucleotide or oligonucleotide can have a label attached to the C5 position of a pyrimidine base or the C7 position of a 7-deazapurine base via a cleavable linker moiety.
[0268] Nucleotide can be marked at the site on sugar or nucleobase.As known in the art, "nucleotide" is composed of nitrogenous base, sugar and one or more phosphate groups.In RNA, the sugar is ribose, and in DNA it is deoxyribose, that is, the sugar lacking the hydroxyl group present in ribose.Nitrogenous base is a derivative of purine (e.g., deazapurine, 7-deazapurine) or pyrimidine.Purine is adenine (A) and guanine (G), and pyrimidine is cytosine (C) and thymine (T), or in the case of RNA it is uracil (U).The C-1 atom of deoxyribose is bonded to the N-1 of pyrimidine or the N-9 of purine.Nucleotide is also the phosphate ester of nucleoside, wherein esterification occurs on the hydroxyl group of C-3 or C-5 attached to sugar.Nucleotide is usually monophosphate, diphosphate or triphosphate.
[0269] Although bases are commonly referred to as purines or pyrimidines, it will be appreciated by the skilled artisan that derivatives and analogs that do not change the ability of a nucleotide or nucleoside to undergo Watson-Crick base pairing are available. "Derivative" or "analog" means a compound or molecule whose core structure is identical or very similar to that of the parent compound, but which has a chemical or physical modification that allows the derived nucleotide or nucleoside to be connected to another molecule, such as a different or additional side group. For example, the base can be a deazapurine. In a particular embodiment, the derivative should be able to undergo Watson-Crick pairing. "Derivatives" and "analogs" also include, for example, synthetic nucleotides or nucleoside derivatives with modified base moieties and / or modified sugar moieties. Such derivatives and analogs are discussed in, for example, Scheit, Nucleotide analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90: 543-584, 1990. Nucleotide analogs may also include modified phosphodiester bonds, including phosphorothioate bonds, phosphorodithioate bonds, alkylphosphonate bonds, aniline phosphonate bonds, phosphoramidite bonds, and the like.
[0270] In a particular embodiment, the nucleotide of the label can be enzymatically incorporable and enzymatically extendable. Therefore, the joint portion can have enough length to connect the nucleotide to the compound so that the compound does not significantly interfere with the overall binding and recognition of the nucleic acid replicator to the nucleotide. Therefore, the joint can also include a spacer unit. The spacer distance is, for example, the distance of the nucleotide base from the cleavage site or label.
[0271] The present disclosure also encompasses polynucleotides incorporating nucleotides described herein. Such polynucleotides may be DNA or RNA composed of deoxyribonucleotides or ribonucleotides joined with phosphodiester bonds, respectively. Polynucleotides may include naturally occurring nucleotides combined with at least one modified nucleotide (e.g., labeled with a dye compound) as shown herein, non-naturally occurring (or modified) nucleotides other than the labeled nucleotides described herein, or any combination thereof. Polynucleotides according to the present disclosure may also include non-natural backbone bonds and / or non-nucleotide chemical modifications. It is also contemplated that a chimeric structure consisting of a mixture of ribonucleotides and deoxyribonucleotides comprising at least one labeled nucleotide.
[0272] In some embodiments, the labeled nucleotides described herein comprise or have the structure of Formula (I):
[0273]
[0274] Wherein B is a nucleobase;
[0275] R 4 is H or OH;
[0276] R 5 is an unsubstituted or substituted allyl group such as Where R a , R b , R c , R d and R e Each is independently H, halogen, unsubstituted or substituted C1-C6 alkyl, or C1-C6 haloalkyl;
[0277] R 6 is H, a monophosphate, a diphosphate, a triphosphate, a thiophosphate, a phosphate analog, a reactive phosphorus-containing group, or a hydroxyl protecting group;
[0278] L is a linker containing an allyl moiety as described herein, such as and
[0279] L 1 and L 2 Each is independently an optionally present linker moiety.
[0280] In some embodiments of the nucleotides described herein, R a , R b , R c , R d and R e Each is H. In other embodiments, R a and R b Each is H, and R c , R d and R e At least one of is independently halogen (e.g., fluorine, chlorine) or unsubstituted C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, isobutyl or tert-butyl). c is an unsubstituted C1-C6 alkyl group, and R d and R e Each is H. In another example, R c is H, and R d and R e One or both of are halogen or unsubstituted C1-C6 alkyl. In some embodiments of the nucleotides described herein, R 1a , R 1b , R 2a , R 3a and R 3b Each is H. In other embodiments, R 1a , R 1b , R 2a , 3a and R 3b At least one of is halogen (e.g., fluorine, chlorine) or unsubstituted C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, isobutyl or tert-butyl). In some such cases, R 1a and R 1b Each is H, and R 2a , R 3a and R 3b At least one of them is unsubstituted C1-C6 alkyl or halogen (e.g., R 2a is an unsubstituted C1-C6 alkyl group, and R 3a and R 3b Each is H; or R 2a is H, and R 3a and R 3b One or both of are halogen or unsubstituted C1-C6 alkyl). In one embodiment, the cleavable linker or L comprises (“AOL” connector portion).
[0281] In some embodiments of the nucleotides of Formula (I) described herein, the nucleobase ("B" in Formula (I)) is a purine (adenine or guanine), a deazapurine, or a pyrimidine (e.g., cytosine, thymine, or uracil). In other embodiments, the deazapurine is a 7-deazapurine (e.g., 7-deazaadenine or 7-deazaguanine). Non-limiting examples of B include or their optionally substituted derivatives and analogs. In other embodiments, the labeled nucleobases include the structure
[0282] In some embodiments of the nucleotides of Formula (I) described herein, L 1 exists, and L 1 In some other embodiments, L 1 include In other embodiments, the asterisk * indicates that L 1 The attachment point to a nucleobase (e.g., C5 of a pyrimidine base, or C7 of a 7-deazapurine base). In another embodiment, when the nucleobase is T, L 1 Include or
[0283] In some other embodiments of the nucleotides of Formula (I) described herein, L 2 exists, and L 2 include wherein n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and the phenyl moiety is optionally substituted. In some such embodiments, n is 5, and L 2 The phenyl portion is unsubstituted.
[0284] Can be incorporated with L 1 or L 2 Additional non-limiting examples of linker moieties in include:
[0285]
[0286] Additional linker moieties are disclosed in WO 2004 / 018493 and U.S. Patent Publication Nos. 2016 / 0040225 and 2021 / 0403500, both of which are incorporated herein by reference.
[0287] Some other embodiments of the T nucleotides described herein include:
[0288] wherein Z is -O-CH2-CH=CH2, and n is an integer of 1, 2, 3, 4 or 5.
[0289] Some other embodiments of the A nucleotides described herein include:
[0290] wherein Z is -O-CH2-CH=CH2, and n is an integer of 1, 2, 3, 4 or 5.
[0291] Some other embodiments of the C nucleotides described herein include:
[0292] wherein Z is -O-CH2-CH=CH2, and n is an integer of 1, 2, 3, 4 or 5.
[0293] Additional embodiments of the G nucleotides described herein include:
[0294] wherein Z is -O-CH2-CH=CH2, and n is an integer of 1, 2, 3, 4 or 5.
[0295] Non-limiting exemplary labeled nucleotides as described herein include:
[0296]
[0297]
[0298]
[0299] wherein PG represents a 3' allyl end-capping group as described herein; n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and m is 0, 1, 2, 3, 4, or 5. In one embodiment, n is 5. refers to the point of attachment of the dye to the cleavable linker as a result of the reaction between the amino group of the linker moiety and the carboxyl group of the dye. In one embodiment, p is 5. Refers to the point of attachment of the first / second / third functional moiety to the cleavable linker as a result of the reaction between the amino group of the linker moiety and the carboxyl group of the first / second / third functional moiety. In further embodiments, the nucleotide may be attached to the first / second / third functional moiety via more than one identical cleavable linker (such as AOL-AOL). In addition, the linker may further include an additional PEG spacer as described herein, for example between R and –(CH2) m -between.
[0300] Various fluorescent dyes can be used as detectable labels in the present disclosure, especially those dyes that can be excited by blue light (e.g., about 450nm to about 460nm) or green light (e.g., about 520nm to about 540nm). These dyes can also be referred to as "blue dye" and "green dye" respectively. The example of various types of blue dyes, including but not limited to coumarin dyes, chromoquinoline dyes and containing diboron heterocyclic compounds, is disclosed in U.S. Patent Publication Nos. 2018 / 0094140, 2018 / 0201981, 2020 / 0277529, 2020 / 0277670, 2021 / 0188832, 2022 / 0033900, 2022 / 0195517, 2022 / 0380389 and 2023 / 0313292, and U.S. Serial No. 18 / 342064, each of which is incorporated by reference in its entirety. Examples of green dyes include cyanine or polymethine dyes disclosed in International Publication Nos. WO2013 / 041117, WO2014 / 135221, WO 2016 / 189287, WO2017 / 051201, and WO2018 / 060482A1, each of which is incorporated by reference in its entirety.
[0301] In any of the embodiments of the nucleotides described herein, the nucleotide comprises a 2' deoxyribose moiety (ie, R 4 In certain other aspects, the 2' deoxyribose contains one, two or three phosphate groups at the 5' position of the sugar ring. In other aspects, the nucleotides described herein are nucleotide triphosphates (i.e., -OR in formula (I) 6 to form triphosphate).
[0302] Additional embodiments of the present disclosure relate to oligonucleotides or polynucleotides comprising nucleosides or nucleotides described herein. In some such embodiments, the oligonucleotides or polynucleotides are hybridized with a template or a target polynucleotide. In some such embodiments, the template polynucleotide is fixed on a solid support.
[0303] Additional embodiments of the present disclosure relate to solid supports comprising an array of a plurality of immobilized templates or target polynucleotides, and at least a portion of such immobilized templates or target polynucleotides are hybridized to an oligonucleotide or polynucleotide comprising nucleosides or nucleotides described herein.
[0304] Cleavage conditions for cleavable linkers
[0305] In any of the embodiments of nucleotides or nucleosides described herein, the 3' blocking group and the cleavable linker (and attached label) can be capable of being removed under the same or substantially the same chemical reaction conditions, for example, the 3' blocking group and the detectable label can be removed in a single chemical reaction. In other embodiments, the 3' blocking group and the detectable label are removed in two separate steps.
[0306] The cleavable linkers described herein can be removed or cleaved under various chemical conditions. Non-limiting cleavage conditions include palladium catalysts such as Pd(II) complexes (e.g., Pd(OAc)2, allyl chloride Pd(II) dimer [(allyl)PdCl]2 or Na2PdCl4) in the presence of a water-soluble phosphine ligand such as tris(hydroxypropyl)phosphine (THPP or THP), tris(hydroxymethyl)phosphine and / or tris(2-carboxyethyl)phosphine (TCEP) with or without a reducing agent. In some embodiments, the 3' blocking group can be cleaved under the same or substantially the same cleavage conditions as those used for the cleavable linker.
[0307] Compatible with linearization
[0308] In order to maximize the throughput of nucleic acid sequencing reactions, it is advantageous to be able to sequence multiple template molecules in parallel. Parallel processing of multiple templates can be achieved by using nucleic acid array technology. These arrays are usually composed of a high-density matrix of polynucleotides that are fixed to a solid carrier material.
[0309] WO 98 / 44151 and WO 00 / 18957 all describe nucleic acid amplification methods, it allows amplification product to be fixed on solid support so that array is formed, these arrays are made up of cluster or " colony ", and wherein cluster or " colony " are formed by multiple identical immobilized polynucleotide chains and multiple identical immobilized complementary chains.This type of array is referred to as " clustered array " in this article.The nucleic acid molecules existing in the DNA colony on the clustered array prepared according to these methods can provide the template for sequencing reaction, for example as described in WO 98 / 44152.The product of solid phase amplification reaction (such as those described in WO 98 / 44151 and WO 00 / 18957) is so-called " bridging " structure, these structures are formed by annealing paired immobilized polynucleotide chains and immobilized complementary chains (two chains are attached to the solid support at 5 ' end). In order to provide a more suitable template for nucleic acid sequencing, it is preferred to remove substantially all or at least a portion of one of the immobilized chains of the "bridging" structure to produce a template that is at least partially single-stranded. Therefore, the single-stranded portion of the template will be available for hybridization with a sequencing primer. The process of removing all or a portion of an immobilized chain in a "bridging" double-stranded nucleic acid structure is called "linearization". There are many ways of linearization, including but not limited to enzymatic cleavage, photochemical cleavage or chemical cleavage. Non-limiting examples of linearization methods are disclosed in PCT Patent Publication No. WO 2007 / 010251, U.S. Patent Publication No. 2009 / 0088327, U.S. Patent Publication No. 2009 / 0118128 and U.S. Patent Publication No. 2019 / 0352327, which are incorporated by reference in their entirety.
[0310] In some embodiments, the conditions for removing the 3' blocking group and / or the cleavable linker are also compatible with linearization methods, such as chemical linearization methods involving the use of a Pd complex and a phosphine. In some embodiments, the Pd complex is a Pd(II) complex (e.g., Pd(OAc)2, [(allyl)PdCl]2, or Na2PdCl4), which generates Pd(0) in situ in the presence of a water-soluble phosphine as described herein, with or without a reducing agent.
[0311] Sequencing by Synthesis Implementation and Alternatives
[0312] Alternatively, unlabeled nucleotides and affinity reagents containing fluorescent dyes described herein can also be used to carry out sequencing methods described herein. For example, in the incorporation mixture of step (a), one type, two types, three types or each type of four different types of nucleotides (e.g., dATP, dCTP, dGTP and dTTP or dUTP) can be unlabeled. Each type of four types of nucleotides (e.g., dNTP) has a 3' blocking group to ensure that only a single base can be added to the 3' end of the primer polynucleotide by a polymerase. After incorporating unlabeled nucleotides in step (b), the remaining unincorporated nucleotides are washed away. Then an affinity reagent is introduced, which specifically recognizes and binds to the incorporated dNTP to provide an extension product containing the label of the incorporated dNTP. The use of unlabeled nucleotides and affinity reagents in synthetic sequencing has been disclosed in WO 2018 / 129214 and WO 2020 / 097607. The sequencing method of the modification of the present disclosure using unlabeled nucleotides can include the following steps:
[0313] (a′) contacting a solid support with a sequencing primer under hybridization conditions, wherein the solid support comprises a plurality of target polynucleotides immobilized thereon; and the sequencing primer is complementary to at least a portion of the target polynucleotide;
[0314] (b′) contacting the solid support with an aqueous solution comprising a DNA polymerase and one or more of four different types of unlabeled nucleotides (A, G, C, and T or U), wherein each of the nucleotides comprises a 3′-capping group comprising an unsubstituted or substituted allylic moiety as described herein (e.g., each nucleotide comprises a 3′-allyl-capping group having a 3′-oxygen atom attached thereto) under conditions suitable for DNA polymerase-mediated primer extension. 2′ deoxyribose moiety of
[0315] (c') contacting the extended copy polynucleotide with a set of affinity reagents under conditions where one of the affinity reagents specifically binds to the incorporated unlabeled nucleotide to provide a labeled extended copy polynucleotide;
[0316] (d') imaging the solid support to determine the identity of the incorporated nucleotide (eg, by performing one or more fluorescence measurements of the extended copy polynucleotide to determine the identity of the incorporated nucleotide); and
[0317] (e') contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine in an atmosphere suitable for chemically removing the 3'-allyl blocking group from the incorporated nucleotide to expose the 3'-
[0318] OH groups under conditions for further nucleotide incorporation on the solid support; and
[0319] Steps (b')-(e') are repeated to determine the target polynucleotide sequence.
[0320] In some embodiments of the modified sequencing methods described herein, the method further includes removing the affinity reagent from the incorporated nucleotides. In other additional embodiments, the 3' blocking group and the affinity reagent are removed in the same reaction. In some embodiments, the method further includes step (f'): washing the solid support with a third aqueous washing solution. In other embodiments, steps (b') to (f') are repeated for at least 50, 100, 150, 200, 250 or 300 cycles to determine the target polynucleotide sequence. In some embodiments, the affinity reagent group may include a first affinity reagent that specifically binds to a first type of nucleotide, a second affinity reagent that specifically binds to a second type of nucleotide, and a third affinity reagent that specifically binds to a third type of nucleotide. In other embodiments, each of the first affinity reagent, the second affinity reagent, and the third affinity reagent includes a spectrally distinguishable detectable label. In some embodiments, the affinity reagent may include a protein tag, an antibody (including but not limited to a binding fragment of an antibody, a single-chain antibody, a bispecific antibody, etc.), an aptamer, a knotting element, an affimer, or any other known reagent that binds to the incorporated nucleotides with suitable specificity and affinity. In one embodiment, at least one affinity reagent is an antibody or a protein tag. In another embodiment, at least one of the first type of affinity reagent, the second type of affinity reagent, and the third type of affinity reagent is an antibody or a protein tag comprising one or more detectable labels (e.g., multiple copies of the same detectable label), wherein the detectable label is or includes a biboron dye moiety as described herein.
[0321] Some embodiments include pyrophosphate sequencing technology. Pyrophosphate sequencing detects the release of inorganic pyrophosphate (PPi) when a specific nucleotide is incorporated into a nascent chain (Ronaghi, M., Karamohamed, S., Pettersson, B., Uhlen, M., and Nyren, P. (1996) "Real-time DNA sequencing using detection of pyrophosphate release." Analytical Biochemistry 242 (1), 84-9; Ronaghi, M. (2001) "Pyrosequencing sheds light on DNA sequencing" Genome Res. 11 (1), 3-11; Ronaghi, M., Uhlen, M., and Nyren, P. (1998) "A sequencing method based on real-time pyrophosphate." Science 281 (5375), 363; U.S. Patent Nos. 6,210,891, 6,258,568 and 6,274,320, the disclosures of which are incorporated herein by reference in their entirety). In pyrophosphate sequencing, the released PPi can be detected by immediate conversion to ATP by adenosine triphosphate (ATP) sulfurylase, and the level of ATP generated is detected via photons generated by luciferase. The nucleic acids to be sequenced can be attached to features in an array, and the array can be imaged to capture chemiluminescent signals generated by the incorporation of nucleotides at the features of the array. Images can be obtained after treating the array with a specific nucleotide type (e.g., A, T, C or G). The images obtained after adding each nucleotide type will differ in which features in the array are detected. These differences in the images reflect the different sequence contents of the features on the array. However, the relative position of each feature will remain unchanged in the image. Images can be stored, processed and analyzed using the methods described herein. For example, images obtained after treating the array with each different nucleotide type can be processed in the same manner as exemplified herein for images obtained from different detection channels for a reversible terminator-based sequencing method.
[0322] In another exemplary type of SBS, cycle sequencing is accomplished by stepwise addition of reversible terminator nucleotides comprising, for example, cleavable or photobleachable dye labels, as described, for example, in WO 04 / 018497 and U.S. Pat. No. 7,057,026, the disclosures of which are incorporated herein by reference. This method is commercialized by Solexa (now Illumina, Inc.) and is also described in WO 91 / 06678 and WO 07 / 123,744, each of which is incorporated herein by reference. The availability of fluorescently labeled terminators, in which not only termination can be reversed but also the fluorescent label can be cleaved, facilitates efficient cyclic reversible termination (CRT) sequencing. Polymerases can also be co-engineered to efficiently incorporate and extend from these modified nucleotides.
[0323] Preferably, in the sequencing embodiment based on reversible terminator, the label does not substantially inhibit extension under SBS reaction conditions. However, the detection label can be removable, such as removed by cleavage or degradation. Images can be captured after the label is incorporated into the arrayed nucleic acid feature. In a specific embodiment, each cycle involves four different nucleotide types being delivered to the array simultaneously, and each nucleotide type has a label that is spectrally different. Four images can then be obtained, each image using a detection channel that is selective to one label in the four different labels. Alternatively, different nucleotide types can be added sequentially, and the image of the array can be obtained between each addition step. In such embodiments, each image will show the nucleic acid feature of the nucleotide that has been incorporated with a specific type. Due to the different sequence content of each feature, different feature will be present or not present in different images. However, the relative position of the feature will remain unchanged in the image. The image obtained by such reversible terminator-SBS method can be stored, processed and analyzed as described herein. After the image capture step, the label can be removed, and the reversible terminator part can be removed, so that the subsequent cycle of nucleotide addition and detection can be performed. Removing labels after they have been detected in a particular cycle and before subsequent cycles can provide the advantage of reducing background signal and crosstalk between cycles. Examples of useful labeling and removal methods are set forth below.
[0324] Some embodiments can use the detection of four different nucleotides using less than four different marks.For example, the method and system described in the material of the combined U.S. Patent Publication No. 2013 / 0079232 can be used to perform SBS.As a first example, a pair of nucleotide types can be detected at the same wavelength, but based on the intensity difference of a member in the pair relative to another member, or based on a member in the pair causing a change (for example, via chemical modification, photochemical modification or physical modification) that a signal that is obvious compared with the signal of another member of the pair detected appears or disappears.As a second example, three of the four different nucleotide types can be detected under specific conditions, and the fourth nucleotide type lacks a mark (for example, the minimum detection caused by background fluorescence, etc.) that can be detected under those conditions or detected minimally under those conditions.The first three nucleotide types can be determined to be incorporated into nucleic acid based on the existence of its corresponding signal, and the fourth nucleotide type can be determined to be incorporated into nucleic acid based on the absence of any signal or the minimum detection of any signal.As a third example, a nucleotide type can include a mark detected in two different channels, and other nucleotide types are detected in no more than one channel. The three exemplary configurations described above are not considered mutually exclusive and can be used in various combinations. An exemplary embodiment combining all three examples is a fluorescence-based SBS method that uses a first nucleotide type detected in a first channel (e.g., dATP with a label detected in the first channel when excited by a first excitation wavelength), a second nucleotide type detected in a second channel (e.g., dCTP with a label detected in the second channel when excited by a second excitation wavelength), a third nucleotide type detected in both the first channel and the second channel (e.g., dTTP with at least one label detected in both channels when excited by the first excitation wavelength and / or the second excitation wavelength), and a fourth nucleotide type that lacks a label detected or minimally detected in either channel (e.g., dGTP without a label).
[0325] In addition, as described in the materials of incorporated U.S. Patent Publication No. 2013 / 0079232, a single channel can be used to obtain sequencing data. In such so-called single dye sequencing methods, a first nucleotide type is marked, but the mark is removed after the first image is generated, and a second nucleotide type is marked only after the first image is generated. A third nucleotide type retains its mark in both the first image and the second image, and a fourth nucleotide type remains unmarked in both images.
[0326] Some embodiments can utilize sequencing technology while connecting. Such technology utilizes DNA ligase to incorporate oligonucleotides and recognize the incorporation of such oligonucleotides. Oligonucleotides generally have different labels related to the identity of specific nucleotides in the sequence to which the oligonucleotides hybridize. As with other SBS methods, images can be obtained after the array of nucleic acid features is treated with labeled sequencing reagents. Each image will show the nucleic acid features into which a specific type of label has been incorporated. Due to the different sequence content of each feature, different features will be present or absent in different images, but the relative position of the features will remain unchanged in the image. Images obtained by sequencing methods based on connection can be stored, processed and analyzed as described herein. Exemplary SBS systems and methods that can be used with the methods and systems described herein are described in U.S. Patent Nos. 6,969,488, 6,172,218 and 6,306,597, and the disclosures of these patents are incorporated herein by reference in their entirety.
[0327] Some embodiments can utilize nanopore sequencing (Deamer, DW and Akeson, M. "Nanopores and nucleic acids: prospects for ultrarapid sequencing." Trends Biotechnol. 18, 147-151 (2000); Deamer, D. and D. Branton, "Characterization of nucleic acids by nanopore analysis", Acc. Chem. Res. 35: 817-825 (2002); Li, J., M. Gershow, D. Stein, E. Brandin and J. A. Golovchenko, "DNA molecules and configurations in a solid-state nanopore microscope", Nat. Mater. 2: 611-615 (2003), the disclosures of which are incorporated herein by reference in their entirety). In such embodiments, the target nucleic acid passes through a nanopore. The nanopore can be a synthetic pore or a biological membrane protein, such as α-hemolysin. As the target nucleic acid passes through the nanopore, each base pair can be identified by measuring the fluctuations in the conductivity of the pore. (U.S. Pat. No. 7,001,792; Soni, GV and Meller, "A. Progress toward ultrafast DNA sequencing using solid-state nanopores", Clin. Chem. 53, 1996-2001 (2007); Healy, K. "Nanopore-based single-molecule DNA analysis", Nanomed. 2, 459-481 (2007); Cockroft, SL, Chu, J., Amorin, M. and Ghadiri, MR "A single-molecule nanopore device detects DNA polymerase activity with single-nucleotide resolution", J. Am. Chem. Soc. 130, 818-820 (2008), the disclosures of which are incorporated herein by reference in their entirety). The data obtained from nanopore sequencing can be stored, processed and analyzed as described herein. In particular, according to the exemplary processing of optical images and other images described herein, the data can be processed like an image.
[0328] Some other embodiments of the sequencing method relate to the use of 3'-terminated nucleotides described herein in nanoball sequencing technology, such as those described in U.S. Pat. No. 9,222,132, the disclosure of which is incorporated herein by reference. A large number of discrete DNA nanoballs can be produced by a rolling circle amplification (RCA) process. The nanoball mixture is then distributed on a patterned slide surface containing features that allow a single nanoball to be associated with each position. During the DNA nanoball production process, the DNA is fragmented and then connected to the first of the four adapter sequences. The template is amplified, circularized, and then cleaved with a type II endonuclease. A second set of adapters is added, followed by amplification, circularization, and cleavage. The process is repeated for the remaining two adapters. The final product is a circular template with four adapters, each of which is separated by a template sequence. The library molecules undergo a rolling circle amplification step to produce a large number of concatemers called DNA nanoballs, which are then deposited on a flow cell. Goodwin et al., “Coming of age: ten years of next-generation sequencing technologies,” Nat Rev Genet. 2016;17(6):333-51.
[0329] Some embodiments may utilize methods involving real-time monitoring of DNA polymerase activity. Nucleotide incorporation may be detected by fluorescence resonance energy transfer (FRET) interactions between a polymerase carrying a fluorophore and a γ-phosphate labeled nucleotide (as described, for example, in U.S. Pat. Nos. 7,329,492 and 7,211,414, both of which are incorporated herein by reference), or may be detected with a zero-mode waveguide (as described, for example, in U.S. Pat. No. 7,315,019, which is incorporated herein by reference), and may be detected using fluorescent nucleotide analogs and engineered polymerases (as described, for example, in U.S. Pat. No. 7,405,281 and U.S. Patent Publication No. 2008 / 0108082, both of which are incorporated herein by reference). Illumination can be limited to the z-scale volume around the surface-tethered polymerase, allowing the incorporation of fluorescently labeled nucleotides to be observed with low background (Levene, MJ et al., "Zero-mode waveguides for single-molecule analysis at high concentrations", Science 299, 682-686 (2003); Lundquist, PM et al., "Parallel confocal detection of single molecules in real time", Opt. Lett. 33, 1026-1028 (2008); Korlach, J. et al., "Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nano structures", Proc. Natl. Acad. Sci. USA 105, 1176-1181 (2008), the disclosures of which are incorporated herein by reference in their entirety). Images obtained by such methods can be stored, processed, and analyzed as described herein.
[0330] Some SBS embodiments include detecting the proton released when nucleotides are incorporated into extension products. For example, sequencing based on the detection of the released proton can use the commercially available electrical detectors and related technologies from Ion Torrent (Guilford, CT, Life Technologies subsidiary), or the sequencing methods and systems described in U.S. Patent Publication Nos. 2009 / 0026082, 2009 / 0127589, 2010 / 0137143 and 2010 / 0282617 (all of these patent publications are incorporated herein by reference). The method for amplifying target nucleic acids using kinetic exclusion set forth herein can be easily applied to substrates for detecting protons. More specifically, the method set forth herein can be used to produce amplicon clone populations for detecting protons.
[0331] The above-mentioned SBS method can be advantageously carried out in a variety of formats so that a plurality of different target nucleic acids are manipulated simultaneously. In a specific embodiment, different target nucleic acids can be processed in a common reaction vessel or on the surface of a specific substrate. This allows to conveniently deliver sequencing reagents, remove unreacted reagents and detect incorporation events in a variety of ways. In the embodiment using the target nucleic acid of surface binding, the target nucleic acid can be an array format. In the array format, the target nucleic acid can be usually attached to the surface in a spatially distinguishable manner. The target nucleic acid can be attached by direct covalent attachment, attached to beads or other particles or attached to a polymerase or other molecules attached to the surface to combine. The array can include a single copy of the target nucleic acid at each site (also referred to as a feature portion), or multiple copies with the same sequence can be present at each site or feature portion. Multiple copies can be produced by an amplification method (such as bridge amplification or emulsion PCR as described in further detail below).
[0332] The methods described herein may use arrays having features at any of a variety of densities, including, for example, at least about 10 features / cm 2 , 100 features / cm 2 , 500 features / cm 2 , 1,000 features / cm 2 , 5,000 features / cm 2 , 10,000 features / cm 2 , 50,000 features / cm 2 , 100,000 features / cm 2 , 1,000,000 features / cm 2 , 5,000,000 features / cm 2 or higher.
[0333] The advantage of the method described herein is that they provide rapid and effective detection of multiple target nucleic acids in parallel. Therefore, the present disclosure provides an integrated system that can use technology known in the art (such as those illustrated above) to prepare and detect nucleic acids. Therefore, the integrated system of the present disclosure may include a fluid assembly that can deliver amplification reagents and / or sequencing reagents to one or more fixed DNA fragments, and the system includes components such as pumps, valves, reservoirs, fluid pipelines, etc. The circulation cell can be configured for and / or for detecting target nucleic acids in the integrated system. Exemplary circulation cells are described in, for example, U.S. Patent Publication No. 2010 / 0111768 and U.S. Patent Application No. 13 / 273,666, each of which is incorporated herein by reference. As illustrated for the circulation cell, one or more fluid assemblies of the integrated system can be used for amplification method and detection method. Taking nucleic acid sequencing embodiment as an example, one or more fluid assemblies of the integrated system can be used for the amplification method described herein and for delivering sequencing reagents in sequencing method (such as those illustrated above). Alternatively, the integrated system may include a separate fluid system to perform amplification method and perform detection method. Examples of integrated sequencing systems that can generate amplified nucleic acids and also determine nucleic acid sequences include, but are not limited to, MiSeq TM The ELISA platform (Illumina, Inc., San Diego, CA), and the apparatus described in U.S. Patent Application No. 13 / 273,666, which is incorporated herein by reference.
[0334] The array that wherein polynucleotide has been directly attached to the carrier based on silica is for example disclosed in WO 00 / 06770 (incorporated herein by reference), wherein polynucleotide is fixed on the glass carrier by the reaction between the epoxy side group on glass and the internal amino group on polynucleotide.In addition, polynucleotide can be connected to solid carrier by the reaction of sulfenyl nucleophilic substance and solid carrier, for example, as described in WO 2005 / 047301 (incorporated herein by reference).Another example of the template polynucleotide of solid support is, wherein template polynucleotide is attached to the hydrogel carried on the solid support based on silica or other solid support, for example, as described in WO 00 / 31148, WO 01 / 01143, WO02 / 12566, WO 03 / 014392, U.S. Patent number 6,465,178 and WO 00 / 53812, these patents are separately incorporated herein by reference.
[0335] The specific surface on which the template polynucleotide can be fixed is a polyacrylamide hydrogel. Polyacrylamide hydrogels are described in the references cited above and WO 2005 / 065814, which is incorporated herein by reference. Specific hydrogels that can be used include those described in WO 2005 / 065814 and U.S. Patent Publication No. 2014 / 0079923. In one embodiment, the hydrogel is PAZAM (poly (N- (5-azidoacetamidopentyl) acrylamide-to-acrylamide)).
[0336] The DNA template molecule can be attached to a bead or microparticle, for example, as described in U.S. Pat. No. 6,172,218 (incorporated herein by reference). Attachment to beads or microparticles can be used for sequencing applications. Bead libraries can be prepared, wherein each bead contains a different DNA sequence. Exemplary libraries and methods for their generation are described in the following documents: Nature, 437, 376-380 (2005); Science, 309, 5741, 1728-1732 (2005), each of which is incorporated herein by reference. It is within the scope of the present disclosure to sequence an array of such beads using the nucleotides shown herein.
[0337] The template to be sequenced can form part of an "array" on a solid support, in which case the array can take any convenient form. Therefore, the method of the present disclosure is applicable to all types of high-density arrays, including single-molecule arrays, clustered arrays, and bead arrays. The labeled nucleotides disclosed herein can be used to sequence templates on substantially any type of array (including but not limited to those formed by fixing nucleic acid molecules on a solid support).
[0338] However, the labeled nucleotides of the present disclosure are particularly advantageous in the context of sequencing clustered arrays. In clustered arrays, different regions (commonly referred to as sites or features) on the array include multiple polynucleotide template molecules. Generally speaking, the multiple polynucleotide molecules cannot be individually distinguished by optical means, but are detected as a whole. Depending on the formation mode of the array, each site on the array can include multiple copies of a single polynucleotide molecule (for example, the site is homogeneous for a specific single-stranded nucleic acid species or double-stranded nucleic acid species) or even multiple copies of a small amount of different polynucleotide molecules (for example, multiple copies of two different nucleic acid species). Clustered arrays of nucleic acid molecules can be produced using techniques known in the art. By way of example, WO 98 / 44151 and WO 00 / 18957 (each of which is incorporated herein) describe a method for amplifying nucleic acids, wherein templates and amplification products are both kept fixed on a solid support, so as to form an array consisting of clusters or "colonies" of fixed nucleic acid molecules. The nucleic acid molecules present on the clustered arrays prepared according to these methods are suitable templates for sequencing using nucleotides labeled with dye compounds of the present disclosure.
[0339] The labeled nucleotides disclosed herein can also be used to sequence the templates on the single molecule array. The term "single molecule array" ("SMA") as used herein refers to a polynucleotide molecule population distributed (or arranged) on a solid support, wherein the spacing between any individual polynucleotide and all other polynucleotides of the molecule population makes it possible to individually distinguish individual polynucleotide molecules. Therefore, in some embodiments, the target nucleic acid molecules fixed to the surface of the solid support can be distinguished by optical means. This means that one or more different signals (each signal represents a polynucleotide) will appear in the distinguishable region of the specific imaging device used.
[0340] Single molecule detection can be achieved, wherein the spacing between adjacent polynucleotide molecules on the array is at least 100 nm, more specifically at least 250 nm, more specifically at least 300 nm, and even more specifically at least 350 nm. Therefore, each molecule can be individually resolved and detected as a single molecule fluorescent spot, and the fluorescence from the single molecule fluorescent spot also exhibits single-step photobleaching.
[0341] The terms "individually resolved" and "individually resolved" are used herein to specify that, when visualized, it is possible to distinguish a molecule on an array from its adjacent molecules. The spacing between the individual molecules on the array will be determined in part by the specific techniques used to resolve the individual molecules. The general characteristics of single molecule arrays will be understood by reference to published applications WO 00 / 06770 and WO 01 / 57248, each of which is incorporated herein by reference. Although one use of the nucleotides of the present disclosure is for sequencing reactions while synthesizing, the effectiveness of these nucleotides is not limited to such methods. In fact, these nucleotides can be advantageously used in any sequencing method that requires detection of fluorescent labels attached to the nucleotides incorporated into the polynucleotides.
[0342] In particular, the labeled nucleotides disclosed herein can be used in automated fluorescent sequencing protocols, especially fluorescent dye-terminator cycle sequencing based on the chain termination sequencing method of Sanger and colleagues. Such methods typically use enzymes and cycle sequencing to incorporate fluorescently labeled dideoxynucleotides into primer extension sequencing reactions. The so-called Sanger sequencing method and related protocols (Sanger-type) utilize randomized chain termination of labeled dideoxynucleotides.
[0343] Thus, the present disclosure also encompasses labeled nucleotides that are dideoxynucleotides lacking hydroxyl groups at both the 3' and 2' positions, such dideoxynucleotides being suitable for use in Sanger-type sequencing methods and the like.
[0344] It will be appreciated that the labeled nucleotides of the present disclosure incorporating a 3' blocking group may also be used in Sanger methods and related protocols, since the same effect as that achieved by using dideoxy nucleotides may be achieved by using nucleotides having a 3'-OH blocking group: both prevent incorporation of subsequent nucleotides. In cases where nucleotides according to the present disclosure and having a 3' blocking group are to be used in Sanger-type sequencing methods, it will be appreciated that the dye compound or detectable label attached to the nucleotide does not need to be connected via a cleavable linker, since in each case where a labeled nucleotide of the present disclosure is incorporated; no subsequent incorporation of a nucleotide is required, and therefore no removal of the label from the nucleotide is required.
[0345] Reagent test kit
[0346] Some additional embodiments of the present disclosure relate to a sequencing kit, the kit comprising:
[0347] (a) comprising a DNA polymerase and a doping mixture of nucleotides A, G, C and T or U, wherein:
[0348] (i) the nucleotide comprises a 3′ unsubstituted or substituted allyl group as described herein attached to the 3′ carbon atom (e.g., )'s 2' deoxyribose moiety;
[0349] as well as
[0350] (ii) the DNA polymerase is an altered archaeal DNA polymerase;
[0351] (b) an aqueous deblocking solution comprising a palladium catalyst, a tris(hydroxyalkyl)phosphine, and one or more buffer reagents, the aqueous deblocking solution being suitable for (i) chemically removing the 3′-allyl group from the incorporated nucleotide to expose the 3′-OH group for further nucleotide incorporation on the solid support; and (ii) chemically removing a detectable label attached via a cleavable linker; and
[0352] (c) an aqueous wash solution comprising a Pd(II) scavenger;
[0353] The kit is configured to perform at least about 50, 100, 150, 200, 250 or 300 sequencing by synthesis cycles.
[0354] In other embodiments, the kit may include four types of labeled nucleotides, i.e., fully functionalized nucleotides (A, C, T, and G) described herein, wherein each type of nucleotide includes a 3' allyl blocking group and an AOL linker portion described herein. In other embodiments, G is unlabeled and does not include any cleavable linker. In further embodiments, one or more nucleotides in the remaining three nucleotides (i.e., A, C, and T) include an allylamine or allylamide linker portion described herein. In one embodiment, the kit includes unlabeled ffG, labeled ffA, labeled ffC, and labeled ffT (wherein ffT contains an allylamine or allylamide linker portion between a nucleobase and a detectable label; also referred to as a double bond or DB linker). In other embodiments, the kit includes unlabeled ffG, labeled ffA, labeled ffC-DB, and labeled ffT-DB described herein. In other embodiments, at least one type of nucleotide includes a base attached to a detectable label via a cleavable linker, and the cleavable linker is wherein Z is -O-CH2-CH=CH2; n is an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the base; and ** indicates the point of attachment of the cleavable linker to the detectable label. In other embodiments, the nucleobase of the T nucleotide is attached to the detectable label via a cleavable linker. In other embodiments, each of the at least three nucleotides independently comprises a base attached to the detectable label via a cleavable linker, and the cleavable linker is selected from the group consisting of:
[0355]
[0356] wherein Z is -O-CH2-CH=CH2; n is an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the base; and ** indicates the point of attachment of the cleavable linker to the detectable label.
[0357] In other embodiments, one or more types of nucleotides A, G, C and T or U are unlabeled, and wherein the first type of unlabeled nucleotides comprises a first functional portion, and the kit further comprises a first labeling agent, wherein the first labeling agent comprises one or more first detectable labels and a first binding portion that can specifically bind to the first functional portion of the unlabeled nucleotides of the first type. In some such embodiments, the first functional portion of the unlabeled nucleotides of the first type is bound to the first labeling agent via a cleavable linker as described herein by covalent binding or non-covalent interaction. In some embodiments, two or more types of nucleotides A, G, C and T or U are unlabeled. In other embodiments, each type of the four types of nucleotides is unlabeled, and wherein the second type of unlabeled nucleotides comprises a second functional portion, and the kit further comprises a second labeling agent, wherein the second labeling agent comprises one or more second detectable labels and a second binding portion that can specifically bind to the second functional portion of the unlabeled nucleotides of the second type. In some such embodiments, the second functional portion of the unlabeled nucleotides of the second type is bound to the second labeling agent via a cleavable linker as described herein by covalent binding or non-covalent interaction. In some other embodiments, the unlabeled nucleotide of the third type comprises a third functional part, and the kit further comprises a third labeling agent, wherein the third labeling agent comprises one or more third detectable labels and a third binding part that can specifically bind to the third functional part of the unlabeled nucleotide of the third type. In some such embodiments, the third functional part of the unlabeled nucleotide of the third type is bound to the third labeling agent via a cleavable linker as described herein by covalent binding or non-covalent interaction. In other embodiments, the unlabeled nucleotide of the third type comprises a mixture of unlabeled nucleotides of the third type containing the first functional part and unlabeled nucleotides of the third type containing the second functional part, and wherein the first labeling agent and the second labeling agent are both able to specifically bind to the unlabeled nucleotides of the third type. In some other embodiments, the unlabeled nucleotide of the fourth type cannot specifically bind to any one of the labeling agents in the first labeling agent, the second labeling agent or the third labeling agent. Post-incorporation labeling kits and methods have been described in U.S. Patent Publication No. 2023 / 0383342A1, which is incorporated by reference in its entirety. Non-limiting examples of non-covalent interactions between the functional portion of the nucleotide and the binding portion of the labeling reagent include, but are not limited to, avidin (e.g., streptavidin or neutravidin) and biotin; dinitrophenyl (DNP) moiety and anti-DNP antibody; digoxigenin (DIG) and anti-DIG antibody; β-N-acetylglucosamine (O-GlcNAc) and WGA (lectin); alkylguanine moiety and SNAP- Alkyl chloride part and 3-nitrotyrosine and anti-nitrotyrosine; nickel or cobalt complexes, such as Ni-nitrilotriacetic acid (NTA) and His-Tag; zinc complexes and oligoaspartate proteins. Non-limiting examples of covalent interactions between functional moieties and labeling agents include, but are not limited to, biorthogonal reactions selected from the group consisting of [3+2] dipolar cycloaddition, Diels-Alder cycloaddition, [4+1] cycloaddition, phosphine linkage, or condensation with 2-acylphenylboronic acid. For example, one of the functional moiety and the binding moiety comprises or is norbornene, trans-cyclooctene (TCO), dibenzocyclooctyne (DBCO), or bicyclo[6.1.0]nonyne (BCN), and the other of the functional moiety and the binding moiety comprises or is an azido group. In some other embodiments, one of the functional moiety and the binding moiety comprises or is TCO, and the other of the functional moiety and the binding moiety comprises or is an optionally substituted 1,2,4,5-tetrazine moiety. Cleavable linkers may comprise the following structures:
[0358] wherein Z is -O-CH2-CH=CH2; each of m and n is independently an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the base; and ** indicates the point of attachment of the cleavable linker to the first / second / third functional portion of the unlabeled nucleotide. In some embodiments, m is 2. In other embodiments, n is 4.
[0359] In a specific embodiment, the kit can include at least one labeled 3' blocked nucleotide or nucleoside, and labeled or unlabeled nucleotides or nucleosides. For example, nucleotides labeled with dyes can be provided in combination with unlabeled or natural nucleotides and / or with fluorescently labeled nucleotides or any combination thereof. Combinations of nucleotides can be provided as independent individual components (e.g., one nucleotide type per container or tube) or as nucleotide mixtures (e.g., two or more nucleotides mixed in the same container or tube).
[0360] In the case where the kit includes a plurality of, particularly two or three, or more particularly four 3'-terminated nucleotides labeled with dye compounds, different nucleotides may be labeled with different dye compounds, or one may be dark, not labeled with dye compounds. In the case where different nucleotides are labeled with different dye compounds, a feature of the kit is that the dye compound is a spectrally distinguishable fluorescent dye. As used herein, the term "spectrally distinguishable fluorescent dye" refers to a fluorescent dye that emits fluorescent energy at a wavelength that can be distinguished by a fluorescence detection device (e.g., a commercial capillary-based DNA sequencing platform) when two or more such dyes are present in a sample. When two nucleotides labeled with fluorescent dye compounds are provided in the form of a kit, some embodiments are characterized in that the spectrally distinguishable fluorescent dyes can be excited at the same wavelength, such as, excited by the same laser. When four 3'-terminated nucleotides (A, C, T, and G) labeled with fluorescent dye compounds are provided in the form of a kit, some embodiments are characterized in that two fluorescent dyes in the spectrally distinguishable fluorescent dyes can be excited at one wavelength, and the other two spectrally distinguishable dyes can be excited at another wavelength. Specific excitation wavelengths are 450 nm to 460 nm, or 520 nm to 532 nm.
[0361] In an alternative embodiment, the kit of the present disclosure may include 3'-terminated nucleotides in which the same base is labeled with two or more different dyes. The first nucleotide (e.g., 3'-allyl-terminated T nucleotide triphosphate or 3'-terminated G nucleotide triphosphate) may be labeled with a first dye. The second nucleotide (e.g., 3'-terminated C nucleotide triphosphate) may be labeled with a second dye spectrally different from the first dye, such as a "green" dye that absorbs light at a wavelength less than 600nm, and a "blue" dye that absorbs light at a wavelength less than 500nm, such as 400nm to 500nm, particularly 450nm to 460nm). The third nucleotide (e.g., 3'-terminated A nucleotide triphosphate) may be labeled with a mixture of the first dye and the second dye, or a mixture of the first dye, the second dye, and the third dye, and the fourth nucleotide (e.g., 3'-terminated G nucleotide triphosphate or 3'-terminated T nucleotide triphosphate) may be "dark" and may not include a label. In one example, nucleotides 1 to 4 may be labeled "blue," "green," "blue / green," and dark. To further simplify the instrument, the four nucleotides may be labeled with two dyes excited by a single laser, so that nucleotides 1 to 4 may be labeled "blue 1," "blue 2," "blue 1 / blue 2," and dark.
[0362] In a specific embodiment, the kit may include four labeled 3'-terminated nucleotides (e.g., A, C, T, G), wherein each type of nucleotide comprises the same 3' allyl blocking group and fluorescent label, and wherein each fluorescent label has a different maximum fluorescence value, each fluorescent label can be distinguished from the other three labels. The kit can be such that two or more of the fluorescent labels have similar maximum absorbances but different Stokes shifts. In some other embodiments, one type of nucleotide is unlabeled.
[0363] Although the kit is described herein with a configuration having different nucleotides labeled with different dye compounds as an example, it should be understood that the kit may include 2, 3, 4 or more different nucleotides having the same dye compound. In some embodiments, the kit also includes an enzyme and a buffer suitable for the enzyme to function. In some such embodiments, the enzyme is a polymerase, a terminal deoxynucleotidyl transferase or a reverse transcriptase. In a specific embodiment, the enzyme is a DNA polymerase, such as DNA polymerase 812 (Pol 812) or DNA polymerase 1901 (Pol 1901). In some other embodiments, the kit may include an incorporation mixture as described herein. In other embodiments, the kit containing the incorporation mixture as described herein also includes at least one Pd scavenger (e.g., a Pd(0) scavenger comprising one or more allylic moieties as described herein). The Pd(0) scavenger includes one or more allylic moieties each independently selected from the group consisting of: -O-allyl, -S-allyl, -NR-allyl and -N-allyl. + RR′-allyl, wherein R is H, unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C2-C6 alkenyl, unsubstituted or substituted C2-C6 alkynyl, unsubstituted or substituted C6-C 10 aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C3-C 10 carbocyclyl, or unsubstituted or substituted 5- to 10-membered heterocyclyl; and R′ is H, unsubstituted C1-C6 alkyl, or substituted C1-C6 alkyl. In some such embodiments, the Pd(0) scavenger incorporated into the solution comprises one or more -O-allyl moieties as described herein in relation to the sequencing method.
[0364] Other components to be included in such kits may include buffers, etc. Nucleotides of the present disclosure and any other nucleotide components including mixtures of different nucleotides may be provided in a concentrated form in a kit and diluted before use. In such embodiments, a suitable dilution buffer may also be included. For example, the mixture kit may include one or more buffers selected from the following: primary amines, secondary amines, tertiary amines, natural amino acids or non-natural amino acids, or a combination thereof. In other embodiments, the buffer incorporated into the mixture includes ethanolamine or glycine, or a combination thereof.
[0365] Similarly, one or more components of the components identified in the methods shown herein can be included in the kit of the present disclosure. In other embodiments, the kit can include a palladium catalyst as described herein. In some embodiments, the Pd catalyst is produced by mixing a Pd (II) complex (i.e., a Pd precatalyst) with one or more water-soluble phosphines as described herein. In some such embodiments, the kit comprising the Pd catalyst is a cleavage mixture kit. In other embodiments, the cleavage mixture kit may contain [Pd (allyl) Cl] 2 or Na 2 PdCl 4 and a water-soluble phosphine (tris (hydroxyalkyl) phosphine, such as THPP) to generate an active Pd (0) substance. The molar ratio of the Pd(II) complex (e.g., Pd(allyl)Cl]2 or Na2PdCl4) to the water-soluble phosphine (e.g., THP) can be about 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5, or 1:10. In additional embodiments, the lysis mixture kit can also include one or more buffer reagents selected from the group consisting of primary amines, secondary amines, tertiary amines, carbonates, phosphates, and borates, and combinations thereof. Non-limiting examples of buffer reagents in the lysis mixture kit are selected from the group consisting of ethanolamine (EA), tris(hydroxymethyl)aminomethane (Tris), glycine, carbonate, phosphate, borate, dimethylethanolamine (DMEA), diethylethanolamine (DEEA), N,N,N′,N′-tetramethylethylenediamine (TEMED), and N,N,N′,N′-tetraethylethylenediamine (TEEDA), 2-piperidineethanol (also known as (2-hydroxyethyl)piperidine, which has the following structure: ), and combinations thereof. In one embodiment, the lysis mixture kit comprises DEEA. In other embodiments, the lysis mixture kit contains (2-hydroxyethyl)piperidine.
[0366] In other embodiments, the kit may include one or more palladium scavengers (e.g., Pd(II) scavengers described herein). In some such embodiments, the Pd(II) scavenger is in the post-lysis wash buffer. In one embodiment, the post-lysis wash buffer kit includes L-cysteine or a salt thereof.
[0367] In any of the embodiments of the kits described herein, the Pd scavenger (eg, a Pd(0) or Pd(II) scavenger described herein) is in a separate container / compartment from the Pd catalyst.
[0368] The present disclosure also provides a box for use with a sequencing device, comprising a plurality of chambers, wherein one or more of the plurality of chambers are used with a kit as described herein. For example, the box may contain two or more separate chambers, one chamber containing an aqueous lysis mixture as described herein, and another chamber containing an incorporation mixture as described herein.
[0369] Example
[0370] Additional embodiments are disclosed in more detail in the following examples, which are not intended to limit the scope of the claims in any way.
[0371] Example 1. Pd pyrolysis solution kinetics study
[0372] In this example, the efficiency of the Pd(0) cleavage mixture generated in situ from Na2PdCl4 and THPP in a molar ratio of 1:3.5 in a buffer solution containing (2-hydroxyethyl)piperidine at pH about 9.8 was investigated. T nucleosides with two different 3′-capping groups were used: 3′-O-allyl-T-5′-OH and 3′-AOM-T-5′-OH (the 3′-AOM capping group has a structure attached to the 3′ carbon atom of the nucleotide ). This study compared the effectiveness of the Pd cleavage mixture in cleaving 3′-allyl end groups and 3′-AOM end groups. Figure 1 As shown, the Pd cleavage efficiency on both capping groups is very comparable and the cleavage of the 3' capping group is almost complete after 30 min.
[0373] Example 2. Synthesis of 3′-allyl-terminated fully functionalized nucleotides (ffN)
[0374] Synthesis Example of 3′-allyl ffT
[0375]
[0376] 5′-O-(tert-Butyldiphenylsilyl)-3′-O-allyl-5-iodo-2′-deoxyuridine (T2)
[0377] Sodium hydride (200 mg, 5 mmol) was suspended in 5 mL of anhydrous tetrahydrofuran in a flask under nitrogen. A solution of 5-iodo-5′-TBDPS-2′-deoxyuridine T1 (1 g, 1.68 mmol) in 10 mL of anhydrous THF was then added dropwise at 0°C. The reaction was then warmed to room temperature and stirred for 30 minutes, and then allyl bromide (430 μL, 5 mmol) was added dropwise at room temperature. The reaction was stirred overnight at room temperature, then quenched with 300 μL of acetic acid, diluted with 100 mL of water and extracted with 100 mL of ethyl acetate. The organic phase was washed with 100 mL of water and 100 mL of brine. The organic phase was dried with MgSO4, filtered and evaporated to dryness. The residue was purified by flash chromatography on silica gel on a Biotage system (SNAPSfar 25 g, gradient 100% DCM to 75:25 DCM / EtOAc). Yield: 724 mg (1.14 mmol), 68%. TLC (EtOAc / DCM 2:8): R f 0.7. 1 H NMR (400MHz, d6-DMSO): δ (ppm) 11.76 (s, 1H, NH), 8.01 (s, 1H, C-6), 7.65 (ddd, J=7.9, 4.9, 1.7Hz, 4H, Ph), 7.55–7.40 (m, 6H, Ph), 6.04 (dd, J=8.2,5.9Hz,1H,1′-CH),5.87(ddt,J=17.2,10.5,5.3Hz,1H,O-CH2-CH=),5.23(dq,J=17.3,1.8Hz,1H,CHH=),5.15(dq,J=10.4,1.5Hz,1 4.11 (dt, J = 5.4, 2.4 Hz, 1H, 3′-CH), 4.06–4.00 (m, 1H, 4′-CH), 3.95 (tt, J = 3.9, 1.5 Hz, 2H, CH2allyl), 3.85 (dd, J = 11.3, 4.0 Hz, 1H, 5′-CHH), 3.73 (dd, J = 11.3, 4.5 Hz, 1H, 5′-CHH), 2.36–2.27 (m, 1H, 2′-CHH), 2.22 (ddd, J = 13.9, 8.3, 6.1 Hz, 1H, 2′-CHH), 1.03 (s, 9H, tBu). LC-MS (ES and CI): (positive ion) m / z 633 (M+H + ),655(M+Na + ); (negative ion) m / z 631 (MH + ).
[0378] 5′-O-(tert-butyldiphenylsilyl)-3′-O-allyl-5-[3-(2,2,2-trifluoroacetamido)- [propyl]-2′-deoxyuridine (T3)
[0379] 5'-O-(tert-butyldiphenylsilyl)-3'-O-allyl-5-iodo-2'-deoxyuridine (T2) (401 mg, 0.634 mmol), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (24 mg, 0.05 mmol, XPhos), [3-(2,2,2-trifluoroacetamido)]-allylboronic acid pinacol ester (354 mg, 1.27 mmol) and allylpalladium(II) chloride dimer (9 mg, 0.025 mmol) were dissolved in 6 mL of anhydrous dimethylformamide and degassed by bubbling with nitrogen for 10 minutes. Then a solution of Cs2CO3 (412 mg, 1.27 mg) in 0.6 mL of water was added and the reaction was heated to 45°C. After 1 hour, the reaction was diluted with 100 mL of ethyl acetate and washed with 2 x 100 mL of water and 100 mL of brine. The organic phase was dried over MgSO4, filtered and evaporated to dryness. The residue was purified by silica gel flash chromatography on a Biotage system (SNAP Sfar 25g, gradient 100% DCM to 7:3 DCM / EtOAc). Yield: 282 mg (0.429 mmol), 68%. TLC (EtOAc / DCM 2:8): R f 0.5. 1 H NMR (400MHz, d6-DMSO): δ (ppm) 11.52 (s, 1H, NH), 9.62 (t, J = 5.7Hz, 1H), 7.95 (s, 1H, C-6), 7.70–7.59 (m, 4H, Ph), 7.53–7.38 (m, 6H, Ph), 6.45 (dt ,J=15.8,6.3Hz,1H,Ar-CH=CH),6.11(t,J=7.1Hz,1H,1′-CH),5.99(d,J=15.9Hz,1H,Ar-CH=,5.89(ddt,J=17.3,10.6,5.3Hz,1H,O-CH2-CH=),5 .26 (dq, J = 17.3, 1.8 Hz, 1H, CHH =), 5.16 (dq, J = 10.4, 1.5 Hz, 1H, CHH =), 4.17 (dt, J = 6.3, 3.3 Hz, 1H, 3′-CH), 4.08–3.94 (m, 3H, 4′-CH, O-CH2-All), 3.88 (dd, J = 11.1, 4.7 Hz, 1H, 5′-CHH), 3.77 (m, 3H, 5′-CHH, CH2-NHTFA), 2.34–2.25 (m, 2H, 2′-CH2), 1.01 (s, 9H, tBu). LC-MS (ES and CI): (positive ion) m / z 658 (M+H + ); (negative ion) m / z 656 (MH+ ).
[0380] 3′-O-allyl-5-[3-(2,2,2-trifluoroacetamido)-allyl]-2′-deoxyuridine (T4)
[0381] Under N2 atmosphere, 5'-O-(tert-butyldiphenylsilyl)-3'-O-allyl-5-[3-(2,2,2-trifluoroacetamido)-allyl]-2'-deoxyuridine (T3) (470 mg, 0.743 mmol) was dissolved in dry THF (6 mL), and then a solution of 1.0 M TBAF in THF (390 μL, 0.89 mmol) was added. The solution was stirred at room temperature for 18 hours, and then TLC (EtOAC / DCM 1:1) showed completion. The solution was diluted with 100 mL EtOAc, then 50 mL saturated NaH2PO4 (pH=3), and washed with 2x50 mL water. The organic phase was dried over MgSO4, filtered and evaporated to dryness. The residue was purified by silica gel flash chromatography on a Biotage system (SNAP Sfar 10 g, gradient 100% DCM to 1:1 DCM / EtOAc). Yield: 218 mg (520 mmol), 70%. TLC (EtOAc / DCM 1:1): R f 0.5. 1 H NMR (400MHz, d6-DMSO): δ (ppm) 11.47 (s, 1H, NH), 9.68 (t, J = 5.7Hz, 1H, NHTFA), 8.03 (s, 1H, H-6), 6.47 (dt, J = 15.9, 6.2Hz, 1H, Ar-CH = CH ),6.21(d,J=16.0Hz,1H,Ar-CH=),6.12(dd,J=7.9,6.0Hz,1H,1′-CH)5.90(ddt,J=17.3,10.5,5.3Hz,1H,O-CH2-CH=),5.28(dq,J=17.3 ,1.8Hz,1H,CHH=),5.16(m,2H,CHH=,5′-OH),4.13(dt,J=5.5,2.6Hz,1H,3′-CH),4.03–3.94(m,3H,4′-CH,O-CH2-All),3.88(t,J=6.0Hz,2H,CH2-NHTFA),3.67–3.54(m,2H,5′-CH2),2.28(ddd,J=13.6,6.0,2.7Hz,1H,2′-CH2),2.20(ddd,J=13.7,7.9,5.8Hz,1H,2′-CH2). LC-MS (ES and CI): (positive ion) m / z 420(M+H + ),442(M+Na +); (negative ion) m / z 418 (MH + ).
[0382] 5′-O-triphosphate-3′-O-allyloxymethyl-5-(3-aminoallyl)-2′-deoxyuridine (T5)
[0383] 3′-O-allyl-5-[3-(2,2,2-trifluoroacetamido)-allyl]-2′-deoxyuridine (T4) (210 mg, 0.501 mmol) was dried over P2O5 under reduced pressure for 18 hours. Anhydrous triethyl phosphate (2 mL) and some freshly activated The reaction flask was then cooled to -15°C in an ice / salt bath. Freshly distilled POCl3 (56 μL, 0.601 mmol) was added dropwise, followed by the dropwise addition of Proton (160mg, 0.75mmol). After addition, the reactant was further stirred for 15 minutes at 0 ℃. Then, a 0.5M solution of bis-tri-n-butylammonium pyrophosphate (1.3g, 2.50mmol) in anhydrous DMF was quickly added, followed by the addition of tri-n-butylamine (537μL, 2.25mmol). The reaction was taken out from the bath and stirred at room temperature for 10 minutes, then quenched into 1M triethylammonium bicarbonate aqueous solution (TEAB, 20mL), and further stirred at room temperature for 4 hours. The solution was then extracted with 30mL ethyl acetate. The aqueous phase was evaporated under reduced pressure, and then 35% ammonia aqueous solution (20mL) was added to the residue and the mixture was stirred at room temperature for 4 hours. The solvent was evaporated under reduced pressure, and the residue was resuspended in 10mL0.1M TEAB, and filtered. First, the filtrate was purified by ion exchange chromatography on DEAE-Sephadex A25 (100g). The column was eluted with a linear gradient of aqueous triethylammonium bicarbonate (TEAB, from 0.1 M to 0.8 M in 1 L). The fractions containing triphosphate were pooled and the solvent was evaporated to dryness under reduced pressure. The crude material was further purified by preparative HPLC using a YMC-Pack-Pro C18 column eluted with 0.1 M TEAB and acetonitrile. Compound T5 was obtained as a triethylammonium salt. Yield: 195 μmol (39%). 11H NMR (400 MHz, D2O): δ (ppm) 8.15 (s, 1H, H-6), 6.50 (d, J = 15.9 Hz, 1H, Ar-CH=), 6.38 (dt, J = 16.0, 6.5 Hz, 1H, Ar-CH=CH-), 6.29 (dd, J = 8.2, 5.9 Hz, 1H, 1′-CH), 5.91 (ddt, J = 17.0, 10.3, 5.9 Hz, 1H O-CH2-CH=), 5.30 (dq, J = 17.3, 1.5 Hz, 1H, CHH=), 5.24–5.16 (m, 1H, CHH=), 4.41 (dt, J = 5.9, 2.0 Hz, 1H, 3′-CH), 4.33 (m, 1H, 4’-CH), 4.22 (ddd, J = 11.8, 4.1, 2.4 Hz, 1H, 5’-CHH), 4.15 (ddd, J = 11.9, 6.2, 2.5 Hz, 1H, 5’-CHH), 4.07 (ddt, J = 5.8, 2.3, 1.3 Hz, 2H, =CH-CH2-O), 3.65 (dd, J = 6.6, 1.1 Hz, 2H, CH2-NH2), 3.12 (q, J = 7.3 Hz, Et3N + ), 2.47 (ddd, J = 14.3, 6.0, 2.1 Hz, 1H, 2’-CHH), 2.27 (ddd, J = 14.2, 8.3, 5.8 Hz, 1H, 2’-CHH), 1.20 (t, J = 7.3 Hz,, Et3N + ). LC-MS (ES and CI): (negative ion) m / z 562 (M-H + ).
[0384] Synthesis of ffT(DB)-3′All-AOL-NR550s0
[0385]
[0386] AOL-NR550s0 carboxylate (0.012mmol) was co-evaporated with 2x2mL anhydrous N, N'-dimethylformamide (DMF) and then dissolved in 1.5mL anhydrous N, N'-dimethylacetamide (DMA). N, N-diisopropylethylamine (17μL, 0.1mmol) was added, followed by N, N, N', N'-tetramethyl-O-(N-succinimidyl) uronium tetrafluoroborate (TSTU, 140μL of 100mM DMF solution, 0.014mmol). The reaction was stirred at room temperature under nitrogen for 1 hour. Meanwhile, an aqueous solution of triphosphate T5 (0.01mmol) was evaporated to dryness under reduced pressure and resuspended in 150μL of 0.1M triethylammonium bicarbonate (TEAB) aqueous solution. The activated AOL-NR550s0 carboxylate solution was added to the triphosphate, and the reaction was stirred at room temperature for 18 hours and monitored by RP-HPLC. The crude product was first purified by ion exchange chromatography on DEAE-Sephadex A25 (25 g) using a gradient elution of 0.1 M TEAB / acetonitrile 8:2 to 1 M TEAB / acetonitrile 8:2. The fractions containing the triphosphate were collected, and the solvent was evaporated to dryness under reduced pressure. The crude material was further purified by preparative RP-HPLC using a YMC-Pack-Pro C18 column with 0.1 M TEAB and acetonitrile elution. LC-MS (ES): (negative ion) m / z 1526 (M-2H + +Na + ),752(M-2H + RP-HPLC (YMC-Packpro C18, 250x4.6 mm, gradient 5% to 60% acetonitrile / 0.1 M TEAB, 20 min, flow rate 1 mL / min): t R =18.3min.
[0387] Synthesis of ffT(PA)-3′All-AOL-NR550s0
[0388]
[0389] AOL-NR550s0 carboxylate (0.015mmol) was co-evaporated with 2x 2mL of anhydrous N, N'-dimethylformamide (DMF) and then dissolved in 2mL of anhydrous N, N'-dimethylacetamide (DMA). N, N-diisopropylethylamine (17μL, 0.1mmol) was added, followed by N, N, N', N'-tetramethyl-O-(N-succinimidyl) uronium tetrafluoroborate (TSTU, 180μL of 100mM DMF solution, 0.018mmol). The reaction was stirred at room temperature under nitrogen for 1 hour. Meanwhile, an aqueous solution of 5'-O-triphosphate-3'-O-allyl-5-(3-aminopropargyl)-2'-deoxyuridine (0.01mmol) was evaporated to dryness under reduced pressure and resuspended in 200μL of 0.1M triethylammonium bicarbonate (TEAB) aqueous solution. The activated dye-linker solution was added to the triphosphate and the reaction was stirred at room temperature for 18 hours and monitored by RP-HPLC. The crude product was first purified by ion exchange chromatography on DEAE-Sephadex A25 (25 g) with a gradient elution from 0.1 M TEAB / acetonitrile 8:2 to 1 M TEAB / acetonitrile 8:2. The fractions containing the triphosphate were pooled and the solvent was evaporated to dryness under reduced pressure. The crude material was further purified by preparative RP-HPLC using a YMC-Pack-Pro C18 column eluted with 0.1 M TEAB and acetonitrile. Yield: 65 μmol, (65%). LC-MS (ES): (negative ion) m / z 1502 (MH + ),750(M-2H + RP-HPLC (YMC-Packpro C18, 250x4.6 mm, gradient 5% to 60% acetonitrile / 0.1 M TEAB, 20 min, flow rate 1 mL / min): t R 18.2min.
[0390] Synthesis of ffT(DB)-3′All-(AOL)2-LC-biotin
[0391]
[0392] (AOL) 2-LC-biotin carboxylate (0.01 mmol) was co-evaporated with 2x2 mL of anhydrous N, N'-dimethylformamide (DMF) and then dissolved in 1 mL of anhydrous N, N'-dimethylacetamide (DMA). N, N-diisopropylethylamine (8.7 μL, 0.05 mmol) was added, followed by N, N, N', N'-tetramethyl-O-(N-succinimidyl) uronium tetrafluoroborate (TSTU, 110 μL of 100 mM DMF solution, 0.011 mmol). The reaction was stirred at room temperature under nitrogen for 1 hour. At the same time, an aqueous solution of triphosphate T5 (0.005 mmol) was evaporated to dryness under reduced pressure and resuspended in 100 μL of 0.1 M triethylammonium bicarbonate (TEAB) aqueous solution. The activated (AOL) 2-LC-biotin carboxylate solution was added to the triphosphate and the reaction was stirred at room temperature for 18 hours and monitored by RP-HPLC. The crude product was purified by preparative RP-HPLC using a YMC-Pack-Pro C18 column eluted with 0.1 M TEAB and acetonitrile. LC-MS (ES): (negative ion) m / z 1625 (MH + ),812(M-2H + RP-HPLC (YMC-Packpro C18, 250x4.6 mm, gradient 5% to 50% acetonitrile / 0.1 M TEAB, 20 min, flow rate 1 mL / min): t R 17.9min.
[0393] Example 3. 3′-allyl cleavage studies by palladium catalysts
[0394] The rate of 3′-allyl deprotection by palladium in solution was measured using model compounds T6 and T7 and compared to the deprotection rate of 3′-AOM model compound A1. In a typical 400 μL reaction, Pd(0)[tris(3-hydroxypropyl)phosphine] was added to a 0.1 mM solution of the substrate in 0.1 M DEEA buffer pH 9.8. x The complex solution was added to a final palladium concentration of 1 mM. The reaction was incubated at room temperature in a capped tube and 20 μL aliquots of the reaction were taken at set time points, immediately quenched with 10 μL of 0.25 M H2O2 / EDTA 1:1, and then analyzed by UHPLC for the formation of the corresponding 3′-OH product. The formation of 3′-OH product over time is shown in Figure 2The data showed that the deprotection rate of compound T6 (3′-allyl (DB)), which contains a 3′-allyl end capping group and a double bond sidearm, was approximately 1.5 times slower than that of compound A1 (3′-AOM). However, incomplete deprotection was observed for compound T7 (3′-allyl (PA)), even after 30 minutes of incubation. Several side products were observed in the UHPLC trace generated from T7, indicating that the triple bond sidearm on thymidine was not inert to the palladium reagent used.
[0395]
[0396] Example 4. Preparation of WT(PA)-3′All-AOL-NR550s0 and WT(DB)-3′Allyl-AOL-NR550s0 Sequencing experiments
[0397] Using blue / green 2-excitation / 1-emission chemistry and corresponding dye sets (blue ffC, dual blue / green ffA, and dark ffG), the Illumina iSeq100 TM The sequencing compatibility of 3′-allyl fully functionalized T, ffT(PA)-3′-All-AOL-NR550s0 and ffT(DB)-3′All-AOL-NR550s0 was tested. In addition to ffT, the following nucleotides were also included in the incorporation mixture: dark G, ffA(DB)-AOM-AOL-chromene quinoline dye A, ffC(DB)-AOM-AOL-coumarin dye B. The ffA, ffC and ffG used in the experiment each contained 3′-AOM as the 3′ capping group. Pd(0)[THP] x Solution was used as lysis reagent, and 10 mM sodium thiosulfate and lipoic acid were used as clearing agents in post-lysis washes. PhiX library was used as template in a separate single read 1x150 cycle experiment. The main metrics of the sequencing experiment are shown in Figure 3A and Figure 3B and Table 1, compared with a control experiment performed with 3′-AOM ffT (ffT(DB)-3′AOM-AOL-NR550s0).
[0398] Chromene quinoline dye A is disclosed in U.S. Patent Publication No. 2022 / 0195517A1 (incorporated by reference). When conjugated to a nucleotide, Chromene quinoline dye A has the following structural moiety:
[0399]
[0400] Coumarin dye B is disclosed in U.S. Patent Publication No. 2018 / 0094140A1 (incorporated by reference). When conjugated to a nucleotide, coumarin dye B has the following structural moieties:
[0401]
[0402] When using ffT(PA)-3′All-AOL-NR550s0, the fluorescence intensity (in both the green and blue channels) experienced a sharp decline, while it was comparable between ffT(DB)-3′All-AOL-NR550s0 and ffT(DB)-3′AOM-AOL-NR550s0 experiments. A similar trend was observed in %Q30. For compound ffT(PA)-3′All-AOL-NR550s0, %PhiX error rate and cycle phasing experienced a more dramatic increase. The data indicate that the double-bonded side arm on T is essential for achieving high-quality sequencing indicators with palladium-based cleavage mixtures.
[0403] Table 1.
[0404]
[0405] Example 5. Sequencing experiment using ffT(DB)-3′All-(AOL)2-biotin
[0406] Using blue / green 2-excitation / 2-emission chemistry and corresponding dye sets (blue ffA, blue and green ffC, and dark ffG), the improved Illumina The sequencing compatibility of T, ffT(DB)-3'All-(AOL)2-LC-biotin fully functionalized with 3'-allyl in the post-incorporation labeling workflow was tested above. In addition to ffT, the following nucleotides were included in the incorporation mixture for the post-incorporation labeling workflow: dark G, ffA(DB)-AOM-AOL-BL-coumarin dye C (blue dye), ffA(DB)-AOM-AOL-AF670POPO (known green dye), ffC(DB)-AOM-AOL-coumarin dye C (blue dye), ffC(DB)-AOM-AOL-NR550s0. The ffA, ffC and ffG used in the experiment each contained 3'-AOM as a 3' capping group. An additional step is included after the incorporation step to label the DNA-incorporated ffT(DB)-3′All-(AOL)2-LC-biotin with a multiple green fluorophore-labeled streptavidin conjugate (NR550C4)6-streptavidin. Pd(0)[THP] x Solution was used as lysis reagent and 10 mM sodium thiosulfate was included in the SBS wash buffer. The PhiX library was used as template in a separate single read 1x150 cycle experiment. The main metrics of the sequencing experiment are shown in Figure 4A and Figure 4BAnd in Table 2, compared with a control experiment performed with 3′-AOM ffT (ffT(DB)-3′AOM-AOL-AF550POPOs0). For the control SBS experiment, the following ffT was used: ffT(DB)-AOM-AOL-AF550POPOs0 (green dye), and the remaining ffN was the same as the post-incorporation labeling workflow.
[0407] Coumarin dye C has strong fluorescence and high stability. The dye is disclosed in U.S. Patent Publication No. 2020 / 0277670A1 (incorporated by reference), and when conjugated with FA, it has the following structural part
[0408] Fluorescence intensity (in both green and blue channels) and signal decay between ffT(DB)-3′All-(AOL)2-LC-biotin and standard ffT(DB)-3′AOM-AOL-AF550POPOs0 labeled after incorporation with green dye-streptavidin conjugate are comparable. Similar trends were observed in %Q30, %PhiX error rate and cycle phasing indicators. The data show that the combination of the 3′-allyl end capping group and the double bond side arm on T is compatible with the sequencing-by-synthesis workflow, which includes a post-incorporation labeling step using a dye-labeled conjugate.
[0409] Table 2.
[0410]
[0411]
Claims
1. A method for determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising: (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein: (i) the solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises multiple copies of a target polynucleotide; (ii) the solid support comprises a plurality of different target polynucleotides; and (iii) the sequencing primer is complementary to at least a portion of the different target polynucleotide; (b) contacting the solid support with an aqueous solution comprising a DNA polymerase and nucleotides A, G, C and T or U under conditions suitable for DNA polymerase-mediated primer extension, wherein each nucleotide comprises a 3' allyl capping group attached to a 3' oxygen atom The 2' deoxyribose moiety; (c) imaging the solid support to determine the identity of the incorporated nucleotide; (d) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for chemically removing the 3'-allyl blocking group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support; (e) contacting the solid support with an aqueous washing solution; and (f) Repeating steps (b) to (e) to determine the target polynucleotide sequence.
2. The method according to claim 1, wherein the aqueous solution comprising DNA polymerase in step (b) further comprises a palladium scavenger.
3. The method according to claim 2, wherein the palladium scavenger in step (b) is a Pd(0) scavenger.
4. The process according to any one of claims 1 to 3, wherein the aqueous washing solution in step (e) further comprises a palladium scavenger.
5. The method of claim 4, wherein the palladium scavenger in step (e) is a Pd(II) scavenger.
6. The method according to any one of claims 1 to 5, wherein the aqueous deblocking solution further comprises ascorbate.
7. The method of any one of claims 1 to 6, wherein at least one type of nucleotide comprises a base attached to a detectable label via a cleavable linker.
8. The method of claim 7, wherein the detectable label is a fluorescent dye and the cleavable linker is selected from the group consisting of: wherein Z is -O-CH2-CH=CH2; n is an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the base; and ** indicates the point of attachment of the cleavable linker to the detectable label.
9. The method of any one of claims 1 to 6, wherein the at least three types of nucleotides comprise bases attached to a detectable label via a cleavable linker.
10. The method of claim 9, wherein the detectable label of each of the at least three types of nucleotides is distinguishable from other detectable labels, and the cleavable linker is selected from the group consisting of: wherein Z is -O-CH2-CH=CH2; n is an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the base; and ** indicates the point of attachment of the cleavable linker to the detectable label.
11. A method for determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising: (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein: (i) the solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises multiple copies of a target polynucleotide; (ii) the solid support comprises a plurality of different target polynucleotides; and (iii) the sequencing primer is complementary to at least a portion of the different target polynucleotide; (b) contacting the solid support with an aqueous solution comprising a DNA polymerase and nucleotides A, G, C and T or U under conditions suitable for DNA polymerase-mediated primer extension, wherein: (i) each type of nucleotide of the at least three types of nucleotides independently comprises a base attached to a detectable label via a cleavable linker, and the cleavable linker comprises a moiety selected from the group consisting of: and * indicates the position where the portion is attached to the rest of the nucleotides; (ii) each nucleotide comprises a 3' allyl group attached to the 3' oxygen atom The 2' deoxyribose moiety of (iii) the DNA polymerase is an altered archaeal DNA polymerase; (c) contacting the solid support with a solution comprising one or more free radical scavengers and imaging the solid support to determine the identity of the incorporated nucleotide; (d) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine in an atmosphere suitable for (i) chemically removing the 3'-allyl blocking group from the incorporated nucleotide thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support; and (ii) contacting under conditions that chemically remove a detectable label attached via a cleavable linker; (e) contacting the solid support with an aqueous wash solution comprising a palladium scavenger; and (f) Repeating steps (b) to (e) to determine the target polynucleotide sequence.
12. The method of claim 11, wherein the palladium scavenger in the aqueous washing solution of step (e) is a Pd(II) scavenger.
13. The method according to claim 11 or 12, wherein the aqueous solution comprising DNA polymerase in step (b) further comprises a palladium scavenger.
14. The method of claim 13, wherein the palladium scavenger in step (b) is a Pd(0) scavenger.
15. A method for determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising: (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein: (i) the solid support comprises at least 5,000,000 spatially distinguishable sites / cm2, each of which comprises a plurality of copies of a target polynucleotide; (ii) the solid support comprises a plurality of different target polynucleotides; and (iii) the sequencing primer is complementary to at least a portion of the different target polynucleotide; (b) contacting the solid support with an aqueous solution comprising a DNA polymerase and nucleotides A, G, C and T or U under conditions suitable for DNA polymerase-mediated primer extension, wherein: (i) at least one of the nucleotides comprises a base attached to a detectable label via a cleavable linker; and (ii) each of the nucleotides comprises a 3' allyl end-capping group attached to the 3' oxygen atom The 2' deoxyribose moiety; (c) contacting the solid support with a solution comprising one or more free radical scavengers and imaging the solid support to determine the identity of the incorporated nucleotide; (d) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for (i) chemically removing the 3'-allyl group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support; and (ii) chemically removing the detectable label attached via a cleavable linker; (e) contacting the solid support with an aqueous washing solution; and (f) Repeating steps (b) to (e) to determine the target polynucleotide sequence.
16. The method of claim 15, wherein the aqueous solution comprising DNA polymerase in step (b) further comprises a palladium scavenger.
17. The method of claim 16, wherein the palladium scavenger in step (b) is a Pd(0) scavenger.
18. The method of claim 16 or 17, wherein the aqueous washing solution in step (e) further comprises a palladium scavenger.
19. The method of claim 18, wherein the palladium scavenger in step (e) is a Pd(II) scavenger.
20. The method of any one of claims 1 to 19, wherein the tris(hydroxyalkyl)phosphine is tris(hydroxypropyl)phosphine (THPP).
21. The method of any one of claims 1 to 20, wherein the solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises a concatemer comprising multiple copies of the target polynucleotide.
22. The method of any one of claims 1 to 20, wherein the solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises an immobilized nucleic acid molecule cluster, and the immobilized nucleic acid molecule cluster comprises multiple copies of the target polynucleotide.
23. The method according to any one of claims 1 to 22, wherein the bases of the A and G nucleotides are deazapurines.
24. The method according to any one of claims 1 to 23, wherein the T nucleotide has the following structure:
25. The method of claim 24, wherein the T nucleotide has the following structure:
26. The method according to claim 24 or 25, wherein the T nucleotide has the following structure: in Z is -O-CH2-CH=CH2, and n is an integer of 1, 2, 3, 4 or 5.
27. The method according to any one of claims 1 to 26, wherein the A nucleotide has the following structure:
28. The method of claim 27, wherein the A nucleotide has the following structure:
29. The method according to claim 27 or 28, wherein the A nucleotide has the following structure: in Z is -O-CH2-CH=CH2, and n is an integer of 1, 2, 3, 4 or 5.
30. The method according to any one of claims 1 to 29, wherein the C nucleotide has the following structure:
31. The method of claim 30, wherein the C nucleotide has the following structure:
32. The method of claim 30 or 31, wherein the C nucleotide has the following structure: in Z is -O-CH2-CH=CH2, and n is an integer of 1, 2, 3, 4 or 5.
33. The method of any one of claims 1 to 32, wherein the G nucleotide has the following structure:
34. The method of claim 33, wherein the G nucleotide has the following structure:
35. The method of claim 33 or 34, wherein the G nucleotide has the following structure: in Z is -O-CH2-CH=CH2, and n is an integer of 1, 2, 3, 4 or 5.
36. The method of any one of claims 1 to 22, wherein at least one type of nucleotide has a structure selected from the group consisting of:
37. The method of claim 36, wherein at least one type of nucleotide has a structure selected from the group consisting of:
38. A method for determining the sequence of a plurality of different target polynucleotides in parallel, the method comprising: (a) contacting a solid support with a solution comprising a sequencing primer under hybridization conditions, wherein: (i) the solid support comprises at least 5,000,000 spatially distinguishable sites / cm 2 , the site comprises multiple copies of a target polynucleotide; (ii) the solid support comprises a plurality of different target polynucleotides; and (iii) the sequencing primer is complementary to at least a portion of the different target polynucleotide; (b) contacting the solid support with an aqueous spike-in mixture comprising a DNA polymerase and one or more of the four types of nucleotides A, G, C and T or U under conditions suitable for DNA polymerase-mediated primer extension, wherein: (i) each of the nucleotides comprises a 3' allyl end-capping group attached to the 3' oxygen atom The 2' deoxyribose moiety; (ii) at least two types of nucleotides are unlabeled; and (iii) a first type of unlabeled nucleotide comprising a first functional moiety; (c) contacting the extended copy polynucleotide with an aqueous labeling mixture comprising a first labeling reagent, wherein the first labeling reagent comprises one or more first detectable labels and a first binding portion capable of specifically binding to the first functional portion of the first type of unlabeled nucleotide; (d) imaging the solid support and performing one or more fluorescence measurements to determine the identity of the incorporated nucleotide; (e) contacting the solid support with an aqueous deblocking solution comprising a palladium catalyst and a tris(hydroxyalkyl)phosphine under conditions suitable for (i) chemically removing the 3'-allyl group from the incorporated nucleotide, thereby exposing the 3'-OH group for further nucleotide incorporation on the solid support; (f) contacting the solid support with an aqueous washing solution; and (g) Repeating steps (b) to (f) to determine the target polynucleotide sequence.
39. The method of claim 38, wherein the first functional portion of the first type of unlabeled nucleotide is bound to the first labeling agent via a cleavable linker by covalent binding or non-covalent interaction.
40. A method according to claim 38 or 39, wherein each of the four types of nucleotides in the aqueous incorporation mixture is unlabeled, and a second type of unlabeled nucleotides comprises a second functional portion, wherein the aqueous labeling mixture comprises a second labeling reagent, and the second labeling reagent comprises one or more second detectable labels and a second binding portion capable of specifically binding to the second functional portion of the second type of unlabeled nucleotides.
41. The method of claim 40, wherein the second functional portion of the second type of unlabeled nucleotide is bound to the second labeling agent via a cleavable linker by covalent binding or non-covalent interaction.
42. A method according to claim 40 or 41, wherein the third type of unlabeled nucleotide comprises a third functional portion, wherein the aqueous labeling mixture comprises a third labeling reagent, and the third labeling reagent comprises one or more third detectable labels and a third binding portion capable of specifically binding to the third functional portion of the third type of unlabeled nucleotide.
43. A method according to claim 40 or 41, wherein the third type of unlabeled nucleotides comprises a mixture of the third type of unlabeled nucleotides containing the first functional part and the third type of unlabeled nucleotides containing the second functional part, and wherein the first labeling agent and the second labeling agent are both capable of specifically binding to the third type of unlabeled nucleotides.
44. The method of claim 42 or 43, wherein the fourth type of unlabeled nucleotides is incapable of specifically binding to any of the first labeling agent, the second labeling agent, or the third labeling agent.
45. The method according to any one of claims 38 to 44, wherein the T nucleotide has the following structure:
46. The method of claim 45, wherein the T nucleotide has the following structure:
47. The method of claim 45 or 46, wherein the T nucleotide has the following structure: wherein Z is -O-CH2-CH=CH2, and each of m and n is independently an integer of 1, 2, 3, 4 or 5.
48. The method of any one of claims 38 to 47, wherein the C nucleotide has the following structure:
49. The method of claim 48, wherein the C nucleotide has the following structure:
50. The method of claim 48 or 49, wherein the C nucleotide has the following structure: wherein Z is -O-CH2-CH=CH2, and each of m and n is independently an integer of 1, 2, 3, 4 or 5.
51. The method of any one of claims 38 to 50, wherein the A nucleotide has the following structure:
52. The method of claim 51, wherein the A nucleotide has the following structure:
53. The method of claim 51 or 52, wherein the A nucleotide has the following structure: wherein Z is -O-CH2-CH=CH2, and each of m and n is independently an integer of 1, 2, 3, 4 or 5.
54. The method of any one of claims 38 to 50, wherein the A nucleotide has the following structure:
55. The method of claim 54, wherein the A nucleotide has the following structure:
56. The method of claim 54 or 55, wherein the A nucleotide has the following structure: wherein Z is -O-CH2-CH=CH2, and each of m and n is independently an integer of 1, 2, 3, 4 or 5.
57. The method of any one of claims 38 to 56, wherein the G nucleotide has a structure selected from the group consisting of:
58. The method of any one of claims 1 to 57, wherein said contacting the solid support with a deblocking solution is performed for 4 to 5 seconds.
59. The method of any one of claims 1 to 58, wherein said contacting the solid support with a deblocking solution is performed via continuous flow without pausing incubation.
60. The method of any one of claims 1 to 59, wherein the sequencing cycle is repeated at least about 20, 30, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 times.
61. The method of claim 60, wherein after about 50 repeated cycles, the pre-phase value is less than 0.
18.
62. The method of claim 61, wherein after about 50 repetitive sequencing cycles, the phasing value is less than 0.
18.
63. The method of claim 62, wherein after about 50 repetitive sequencing cycles, the prephase value is less than 0.
07.
64. The method of claim 60, wherein after about 100 repetitive sequencing cycles, the prephasing value is less than 0.10 and the phasing value is less than 0.
10.
65. The method of claim 60, wherein after about 150 repetitive sequencing cycles, the prephasing value is less than 0.25 and the phasing value is less than 0.
25.
66. The method of claim 60, wherein after about 150 repetitive sequencing cycles, the prephasing value is less than 0.10 and the phasing value is less than 0.
10.
67. The method of any one of claims 1 to 66, wherein the deblocking solution further comprises one or more buffer reagents selected from the group consisting of primary amines, secondary amines, tertiary amines, carbonates, phosphates, and borates, and combinations thereof.
68. The method of claim 67, wherein the buffer reagent is selected from the group consisting of ethanolamine (EA), tris(hydroxymethyl)aminomethane (Tris), glycine, carbonate, phosphate, borate, 2-dimethylaminoethanol (DMEA), 2-diethylaminoethanol (DEEA), N,N,N',N'-tetramethylethylenediamine (TEMED), N,N,N',N'-tetraethylethylenediamine (TEEDA) and (2-hydroxyethyl)piperidine, and combinations thereof.
69. The method of any one of claims 1 to 68, wherein the DNA polymerase is an altered Family B archaeal DNA polymerase comprising a 3-amino acid region functionally equivalent or homologous to amino acids 408 to 410 in 9°N DNA polymerase, wherein the first amino acid of the 3-amino acid region is an amino acid selected from the group consisting of isoleucine (I), alanine (A), valine (V), and serine (S); the second amino acid of the 3-amino acid region is an amino acid selected from the group consisting of alanine (A) and glycine (G); and the third amino acid of the 3-amino acid region is an amino acid selected from the group consisting of alanine (A), isoleucine (I), valine (V), leucine (L), threonine (T), and proline (P).
70. A sequencing kit, comprising: (a) comprising a DNA polymerase and a doping mixture of nucleotides A, G, C and T or U, wherein: (i) the nucleotide comprises a 3' allyl group attached to the 3' carbon atom The 2' deoxyribose moiety of (ii) the DNA polymerase is an altered archaeal DNA polymerase; (b) an aqueous deblocking solution comprising a palladium catalyst, a tris(hydroxyalkyl)phosphine, and one or more buffer reagents, the aqueous deblocking solution being suitable for (i) chemically removing the 3'-allyl group from the incorporated nucleotides to expose the 3'-OH group for further nucleotide incorporation on the solid support; and (ii) chemically removing a detectable label attached via a cleavable linker; and (c) an aqueous wash solution comprising a Pd(II) scavenger; The kit is configured to perform at least about 100 cycles of sequencing by synthesis.
71. The kit of claim 70, wherein at least one type of the nucleotide comprises a base attached to a detectable label via a cleavable linker, and the cleavable linker is wherein Z is -O-CH2-CH=CH2; n is an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the base; and ** indicates the point of attachment of the cleavable linker to the detectable label.
72. The kit of claim 71, wherein the nucleobase of the T nucleotide is attached to the detectable label via the cleavable linker.
73. The kit of any one of claims 70 to 72, wherein each of the at least three nucleotides independently comprises a base attached to a detectable label via a cleavable linker, and the cleavable linker is selected from the group consisting of: wherein Z is -O-CH2-CH=CH2; n is an integer of 1, 2, 3, 4 or 5; * indicates the point of attachment of the cleavable linker to the base; and ** indicates the point of attachment of the cleavable linker to the detectable label.
74. A kit according to claim 70, wherein two or more types of nucleotides A, G, C and T or U are unlabeled, and wherein a first type of unlabeled nucleotide comprises a first functional portion, and the kit further comprises a first labeling reagent, wherein the first labeling reagent comprises one or more first detectable labels and a first binding portion capable of specifically binding to the first functional portion of the first type of unlabeled nucleotide.
75. A kit according to claim 74, wherein each of the four types of nucleotides is unlabeled, and wherein a second type of unlabeled nucleotides comprises a second functional portion, and the kit further comprises a second labeling reagent, wherein the second labeling reagent comprises one or more second detectable labels and a second binding portion capable of specifically binding to the second functional portion of the second type of unlabeled nucleotides.
76. A kit according to claim 75, wherein the third type of unlabeled nucleotide comprises a third functional portion, and the kit further comprises a third labeling reagent, wherein the third labeling reagent comprises one or more third detectable labels and a third binding portion capable of specifically binding to the third functional portion of the third type of unlabeled nucleotide.
77. A kit according to claim 75, wherein the third type of unlabeled nucleotides comprises a mixture of the third type of unlabeled nucleotides containing the first functional part and the third type of unlabeled nucleotides containing the second functional part, and wherein the first labeling reagent and the second labeling reagent are both capable of specifically binding to the third type of unlabeled nucleotides.
78. The kit of claim 76 or 77, wherein the fourth type of unlabeled nucleotides is incapable of specifically binding to any of the first, second or third labeling agents.
79. The kit of any one of claims 70 to 78, wherein the dosing mixture further comprises a Pd(0) scavenger.
80. The kit of any one of claims 70 to 79, wherein the tris(hydroxyalkyl)phosphine is tris(hydroxypropyl)phosphine (THPP).
